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 Following liver transplantation, patients require lifelong immunosuppressive care 
and monitoring to prevent organ rejection, drug toxicity, and death.  Traditionally, 
transplant centers use paper-based processes that are not scalable and can lead to 
inefficiencies and deficiencies in information management.  Clinical decision support 
(CDS) tools may help to overcome information management challenges, and a system-
agnostic approach may help to disseminate these tools nationwide.  We sought to inform 
the development of new transplant information systems by analyzing existing information 
systems. 
 To meet this overall objective, we administered a survey and found that all liver 
transplant programs used manual, paper-based processes and nearly all used electronic 
health record (EHR) systems.  Programs also had immunosuppression guidelines with 
similar logic patterns.  Then we analyzed long-term use of a computerized notification 
system at one transplant center and found that a system designed specifically for the 
posttransplant workflow can meet long-term information management needs.  Next, we 
assessed the clinical outcomes associated with computerized notifications for laboratory 
monitoring of immunosuppressive care and found that a system designed specifically for 
the posttransplant workflow was associated with improved clinical outcomes.  Following 
this, we described workflow processes at two transplant centers and found that a 




measures and the satisfaction of performing laboratory monitoring tasks compared to a 
general EHR notification system.  Finally, we administered a questionnaire to 
coordinators using a transplant-specific notification system and identified the usage of 
specific data elements in computerized notifications for posttransplant laboratory 
monitoring. 
 Our findings show that near universal use of EHRs provides an infrastructure for 
implementing CDS tools, and logic patterns for posttransplant laboratory monitoring can 
be generalized to other U.S. transplant centers.  Transplant-specific computerized 
notifications may be part of a system of processes that improve the scalability, quality, 
and satisfaction of patient management by postliver transplant coordinators.  However, 
these systems must be flexible enough to accommodate new immunosuppressants and 
changing or additional parameters used in computerized logic as clinical practice or needs 
of the patient population evolve.  Proactive notifications sent directly to patients 
regarding upcoming due dates via patient portals may also improve patient outcomes.
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 More than 130,000 liver transplantations have been performed in the United 
States since 1988.
1
  Liver transplant recipients require lifelong immunosuppressive care 
to prevent organ rejection, drug toxicity, and death.  Transplant centers face challenges 
when implementing immunosuppressive care protocols, monitoring laboratory and other 
data, and managing the growing set of information for this high-risk patient population.  
As the number of liver transplant recipients increases each year and long-term survival 
rates improve,
1
 transplant centers have a growing pool of patients generating information 
that must be prioritized and managed.  Traditionally, transplant centers have used paper-
based processes to receive or track immunosuppressive laboratory results.  These manual, 
paper-based processes are not scalable and can lead to inefficiencies and deficiencies in 
information management.
2,3
  Concerns about the availability or timeliness of information 
necessary for clinical decision making are not unique to immunosuppression care 
management.
4–8
  However, these problems are exacerbated by growing patient 
populations and the complexity of immunosuppressive care protocols with narrow 
therapeutic indices and regimens that change based on time since transplantation, 
presence of comorbid conditions, and other factors.
9
  Information management challenges 





 Clinical decision support (CDS) tools have improved posttransplant care process 
measures and clinical outcomes.  The biomedical literature includes descriptions of 
computerized transplant management systems,
3,10–14
 but only two publications describe 
the use of more advanced clinical decision support (CDS) for postliver transplant 
immunosuppressive care.
3,10
  One publication describes the use of integrated information 
displays to support physicians and coordinators performing comprehensive 
immunosuppressive care review.
10
  Patients managed with the system experienced 
significantly fewer rejection episodes and tacrolimus toxicity events compared to patients 
managed with the prior paper charting system.  The second publication describes work at 
Intermountain Healthcare (IH) regarding computerized notifications to support nurse 
transplant coordinators as they monitored immunosuppressive care.
3
  Notifications were 
implemented using a CDS infrastructure to automate laboratory monitoring protocols and 
were delivered to an inbox integrated within the electronic health record (EHR).  The 
system led to significant process improvements, such as improved completeness, 
timeliness, and reduced redundancy of laboratory result reporting compared to a manual, 
paper-based approach.  However, both of these CDS tools are system-dependent and thus 
not sharable with other transplant centers. 
 System-agnostic CDS services are a promising approach to promote the 
widespread implementation of CDS across applications and care settings.
15
  Thus, using 
this approach may be an effective method for sharing a CDS tool for posttransplant 
immunosuppressive care laboratory monitoring.  Our motivation was to develop a 
system-agnostic CDS notification system for posttransplant laboratory monitoring.  





is developed, including: 
 What are the information management needs and challenges of laboratory 
monitoring for posttransplant immunosuppressive care? 
 What is the prevalence of prerequisites (eg, EHR infrastructure, availability of 
discrete data, or guidelines amenable to computable logic) necessary to 
implement transplant-specific CDS in U.S. transplant centers? 
 How are computerized notifications for laboratory monitoring used by nurse 
transplant coordinators over time? 
 Do computerized notifications for laboratory monitoring improve the clinical 
outcomes of posttransplant patients? 
 How do computerized notifications impact the workflow of nurse transplant 
coordinators? 
 How satisfied are transplant coordinators with the support of their information 
system with and without transplant-specific CDS? 
 What data elements in a computerized notification message are used by transplant 
coordinators? 
 This dissertation seeks to answer these research questions in order to inform the 
development of a system-agnostic CDS tool for posttransplant laboratory monitoring.  
The goal of this dissertation was to investigate opportunities, barriers, and the impact 
related to implementing computerized notifications to support laboratory monitoring for 
postliver transplant immunosuppressive care.  Chapter 2 includes a summary of the 
findings from a nationwide survey regarding readiness of transplant centers to implement 





the number of transplant centers who may benefit from a system-agnostic CDS tool for 
laboratory monitoring.  Chapter 3 includes a description of the distribution of 
computerized notifications over time, with implications for how to improve notifications 
to meet the evolving needs of patients as time since transplantation increases.  This study 
evaluates whether a system-agnostic CDS tool designed for a posttransplant workflow 
would be used long-term to meet information management needs.  Chapter 4 includes an 
analysis of the clinical impact of computerized notifications on postliver transplant 
immunosuppressive care.  A system-agnostic computerized notification system may have 
a similar impact on clinical outcomes.  Chapter 5 includes a description of the processes 
performed by nurse transplant coordinators for outpatient immunosuppressive care and a 
comparison of the response time to new laboratory results and satisfaction with 
performing tasks among nurse transplant coordinators with or without access to 
transplant-specific computerized notifications.  This analysis identifies the potential 
impact to workflow and process measures that may accompany a system-agnostic CDS 
notification system for posttransplant laboratory monitoring.  Finally, this chapter also 
includes a description of usage of specific data elements presented with computerized 
notifications.  This analysis identifies the data elements that should be included in other 
transplant-specific computerized notification systems. 
The findings described in this dissertation address only part of the scope of 
postliver transplant immunosuppressive care, focusing on laboratory monitoring 
performed by nurse transplant coordinators.  Understanding other processes of 
immunosuppressive care may also help to identify ways in which safety, quality, and cost 





meeting the immunosuppressive care needs of other solid organ transplant recipients 
(such as kidney and heart) are similar.  In addition, other areas in healthcare use similar 
processes to manage laboratory results and medications, including diabetes care and 
anticoagulation therapy.  Such areas may also benefit from an in-depth understanding of 
the processes of care and the prudent application of CDS tools that support the 
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LONGITUDINAL ANALYSIS OF COMPUTERIZED ALERTS FOR  
LABORATORY MONITORING OF POSTLIVER TRANSPLANT 
IMMUNOSUPPRESSIVE CARE 
 
A presentation based on this work was presented at the American Medical Informatics 
Association Annual Symposium Proceedings in November 2015. 
 
A publication based on this work is available from: Jacobs J, Narus SP, Evans RS, Staes 
CJ. Longitudinal Analysis of Computerized Alerts for Laboratory Monitoring of Post-






 More than 65,000 liver transplant patients are currently living in the United 
States.
1
  These patients require lifelong immunosuppressive care and monitoring to 
prevent organ rejection, toxicity, and death following this costly
2
 and complex procedure.  
A capitated model may be used to reimburse providers for the lifelong care of 
posttransplant patients, incentivizing transplant centers to minimize costs.
2
  Achieving 
higher quality care at lower cost is the daunting challenge facing the United States in the 




 Computerized decision support aids have demonstrated potential to support higher 
quality health care.  Their effectiveness has been shown in areas of relatively simple 
logic, such as checking for medication interactions or recognizing laboratory tests with 
out-of-range results.
5,6
  When appropriately applied, such clinical decision support (CDS) 
has been shown to reduce errors, decrease costs, and encourage best practice.
7,8
  The 
Office of the National Coordinator for Health Information Technology (ONC) has 
emphasized the importance of CDS to optimize health care outcomes and the need for its 
widespread adoption.
9




 In 2004, a computerized alerting system was implemented at Intermountain 
Healthcare (IH) to support the laboratory monitoring of postliver transplant patients.
11
  
While internal laboratory results were already available, a data entry program was created 
to input information regarding laboratory results from external laboratories as structured 
data in the EHR.
12





alerts to be generated for all posttransplant patients regardless of laboratory used for 
testing.  Alerts were generated for new, out-of-range, or overdue immunosuppression-
related laboratory testing using automated rules developed by experts in transplant 
management.  The automated rules employed the same logic found in the protocols used 
by nurse transplant coordinators for routine laboratory monitoring.  Alerts were delivered 
to an electronic inbox within the EHR and remained until accepted or rejected.  Nurse 
transplant coordinators could view the alert message along with information useful for 
decision making (eg, date and value of the laboratory result that triggered the alert, date 
of and time since liver transplantation, and hospitalization status).  Coordinators could 
accept or reject the alert, select the reason for the action taken, and leave a narrative 
comment.  As of 2015, the liver transplant team at IH has continued to use the data entry 
system and the CDS alerts developed in 2004 to manage their growing population of over 
500 active liver transplant patients.  A previous study showed that this system led to 
significant improvements in the completeness, timeliness, and reduced redundancy of 
laboratory result reporting.
11
  A more detailed description of the infrastructure, logic, and 
alerts delivered are available in previous publications.
11,13
 
 We found one other study that used CDS to support posttransplant laboratory 
monitoring.
14
  Researchers found evidence that CDS improved clinical outcomes and 
decreased costs during the first year of posttransplant care.  Other transplant centers have 
expressed an interest in implementing CDS to support the lifelong management of their 
posttransplant patient population.
15
  Yet there are studies indicating that CDS may be 
disruptive or no longer used by target users after initial implementation.
16
  While the 





there is a gap in the understanding of how alerts are used by nurse transplant coordinators 
for laboratory monitoring of postliver transplant patients over time, particularly as time 
since transplantation increases. 
 
3.2 Objectives 
 In this study, we aimed to describe alerts delivered to nurse transplant 
coordinators from 2005 to 2012.  Our objectives were to a) describe the alerts delivered 
to nurse transplant coordinators to manage patients after liver transplantation over an 
eight-year period, b) describe the distribution of the alerts and the time to respond to 
alerts as time since transplantation increased, and c) identify opportunities for improving 
alerts in order to improve the management of posttransplant immunosuppressive care. 
 
3.3 Methods 
 The liver transplant program at IH performed 776 liver transplant surgeries from 
January 1, 1988, to December 31, 2012.  The study population included patients who 
received a liver transplant at IH and who were monitored for posttransplant laboratory 
testing of immunosuppressive care by IH nurse transplant coordinators.  We included 
alerts generated between January 1, 2005 and December 31, 2012 for this study.  Since 
individual patient outcomes were not reported for this study, each transplantation was 
included for patients who received multiple liver transplants (n=15).  We classified 
patients as lost to follow-up during a time period when there was a gap of 365 days or 
greater between an alert for overdue tacrolimus laboratory testing and an alert for a new 





they were classified as lost to follow-up.  Patients became active once an alert for a new 
laboratory result was received.  All alerts were triggered by either new (including out-of-
range) or overdue laboratory testing. 
 Data were extracted from the IH enterprise data warehouse (EDW) with the help 
of EDW experts and a transplant center data manager.  Data included 
immunosuppression and related laboratory results, triggered alerts, and hospital 
admission and discharge dates and times. 
 We analyzed alerts based on the year an alert was triggered, time since 
transplantation, hospitalization status, alert type, action taken (accepted or rejected), 
reason given for the action taken, and narrative comments.  Correlations among data 
elements were identified.  We described the response time between alert generation and 
action taken, stratified by time since transplantation.  We also described the time between 
an alert for an overdue laboratory test and an alert for a subsequent new laboratory result 
(including only the first in a series of alerts for overdue testing), stratified by time since 
transplantation.  Time-based results were summarized using a box-and-whisker plot with 
the ends of the whiskers representing the lowest value within 1.5 times the interquartile 
range of the first quartile and the highest value within 1.5 times the interquartile range of 
the third quartile.  Outliers (values outside the whiskers) were not shown. 
 Institutional Review Boards from Intermountain Healthcare and the University of 









 Nurse transplant coordinators received alerts for 564 postliver transplant patients 
from January 1, 2005 to December 31, 2012.  The number of active patients who received 
laboratory monitoring grew from 338 in 2005 to 418 in 2012 (Table 3.1). 
 From January 1, 2005 to December 31, 2012, there were 124,082 computerized 
alerts delivered to nurse transplant coordinators for laboratory monitoring of postliver 
transplant patients.  Coordinators received an average of 42.5 alerts per day over this time 
period, and all alerts were either accepted or rejected.  Nearly all (98.0%) alerts were 
accepted, and 22.8% of alerts were received while the patient was hospitalized.  The most 
common alerts were triggered by new results for creatinine (41.5%) or tacrolimus 
(30.4%) or when patients were overdue for tacrolimus (12.1%) or creatinine (9.8%) 
laboratory testing (Table 3.2). 
 While the number of alerts per patient remained fairly stable, the number of alerts 
per day gradually increased over time (39.0 in 2005, 45.6 in 2012) (Table 3.1).  This 
paralleled an increase in the number of active patients over the same period (338 in 2005, 
418 in 2012), even though the number of transplantations declined.  Alerts for overdue 
laboratory testing constituted a growing proportion of all alerts over time, increasing 
from 19.6% in 2005 to 29.3% in 2012.  There was not a constant change over time in the 
proportion of alerts generated while patients were hospitalized.  The proportion of alerts 
that were rejected decreased from 7.0% in 2005 to 0.6% in 2008 and remained below 
0.6% per year through 2012 (Table 3.1). 
 Among alerts for overdue laboratory testing, few (<1%) alerts were generated 





patients were not hospitalized, 8.3% of overdue creatinine alerts and 8.5% of overdue 
tacrolimus alerts were rejected.  The most common reason for rejecting an alert was due 
to external laboratory results that were available but had not yet been entered into the 
EHR (Table 3.3).  For accepted alerts, coordinators most frequently sent a notification 
letter or indicated that they had previously sought to notify the patient.  No single patient 
constituted more than 1% of alerts for overdue laboratory testing. 
 Conversely, the proportions of alerts generated for hospitalized patients were 
greater among alerts for new laboratory results (range: 13.8-64.5%) than among alerts for 
overdue laboratory testing (Table 3.2).  Whether for hospitalized patients or not, few 
(range: 0-2.2%) alerts for new laboratory results were rejected.  Among actions taken for 
accepted alerts, 100% required no additional action and 48% indicated that the 
coordinator reviewed the results if the patient was hospitalized, but for nonhospitalized 
patients, coordinators responded to accepted alerts in a variety of ways, such as reviewing 
laboratory results, contacting the patient, consulting the physician, or indicating that no 
action was required (Table 3.3). 
 Among alerts received when patients were not hospitalized, the number of alerts 
per day and the proportion of overdue alerts increased over time (Table 3.4), similar to 
the pattern observed overall in Table 3.1.  However, while the proportion of alerts for low 
tacrolimus laboratory results remained stable, the proportions for normal and high 
tacrolimus laboratory results declined over time (normal: 8.9% in 2005, 3.8% in 2012; 
high: 5.3% in 2005, 1.2% in 2012).  Likewise, the proportions of alerts for high creatinine 
laboratory results remained stable while the proportion for normal creatinine laboratory 





laboratory testing decreased from 25% or higher during 2005-2007 (range: 25.0-29.4%) 
to below 3% during 2008-2012 (range: 0.3-2.5%).  The rejection rate for alerts of new 
laboratory results was 2.0% or lower throughout the study. 
 As time since transplantation increased, the number of alerts per patient declined 
from 95 to 21 (excluding 10+ years posttransplant) (Table 3.5).  Likewise, the proportion 
of alerts received while patients were hospitalized decreased from 53.6% during the first 
period to 13.5% in the last period.  Alerts for overdue laboratory testing constituted a 
growing proportion of alerts as time since transplantation increased from 2.0% for 0-3 
months posttransplant to 44.1% for 10+ years posttransplant.  In contrast, the proportion 
of patients with one or more overdue alerts appeared bimodal, with peaks at 3-4 years 
posttransplant and at 10+ years posttransplant.  The proportion of alerts that were rejected 
ranged from 0.8% to 4.0% with no pattern as time since transplantation increased. 
 There was no trend in the response time between alert generation and the action 
taken for nonhospitalized patients by year.  For new laboratory results, the nurse response 
time ranged from a median of 6 to 17 hours by year (Figure 3.1).  For overdue laboratory 
testing, the nurse response time ranged from a median of 5 to 125 hours by year (Figure 
3.2).  However, for both new and overdue laboratory testing, there was a significant drop 
in the median response time to alerts from 2007 to 2008.  
 The response time between alert generation and the action taken for non-
hospitalized patients increased with time since transplantation.  For alerts of new 
laboratory results, the median response time increased from 6 to 17 hours (Figure 3.3).  
For alerts of overdue laboratory testing, the median response time increased from 6 to 23 





median response time for alerts of both new and overdue laboratory testing remained 
fairly stable from 2-3 years posttransplant and beyond. 
 The time between an alert for overdue tacrolimus laboratory testing and the next 
alert for a new tacrolimus laboratory result for nonhospitalized patients increased with 
time since transplantation (Figure 3.5).  The median interval increased from 5.8 to 41.2 
days from 0-3 months to 10+ years posttransplant. 
 
3.5 Discussion 
 While a few studies have explored how computerized alerts support laboratory 
monitoring of patients within the first year after transplantation,
11,14
 no studies have 
analyzed how these alerts are used by nurse transplant coordinators as time since 
transplantation increases for patients beyond the first year.  Our study shows that the 
distribution of alerts generated to support the laboratory monitoring of postliver 
transplant patients changes over time.  As time since transplantation increases, there is a 
greater need to support the process of monitoring patients who are overdue for laboratory 
testing.  In addition, even though the active patient population continued to grow, there 
was a decline in the number of new postliver transplant patients at IH.  This shift in the 
population means that a greater proportion of time must be devoted to monitoring 
patients who are more prone to overdue laboratory testing.  Liver transplantation graft 
failure rates have continued to improve and patients are surviving longer, further 
increasing the need to monitor immunosuppressive care, particularly for overdue 
laboratory testing.  Transplant coordinators must juggle the contrasting needs of recently 





patients who are several years posttransplant and who receive less frequent laboratory 
testing but are more prone to being overdue for testing.  Thus, computerized alerts should 
be implemented in a way that supports the evolving needs of managing this patient 
population. 
 There was a dramatic decrease in rejected alerts for overdue laboratory testing of 
nonhospitalized patients from 25% or greater during 2005-2007 to less than 3% during 
2008-2012.  During the study, 73% of these overdue alerts were rejected due to the 
availability of laboratory results from external laboratories that had not yet been entered 
into the EHR.  The increasing number of overdue alerts generated over time and the 
substantial decrease in the proportion that were rejected after 2007 may indicate that 
additional time dedicated to data entry or implementation of electronic laboratory 
interfaces were used to improve the integration of laboratory results from external 
laboratories.  A nurse transplant coordinator confirmed that an employee had been 
dedicated to data entry of external laboratory results in early 2008.  The challenge of 
integrating external laboratory results as structured data into the EHR is a significant 
barrier to the widespread use of CDS.
15
  Considerable effort, both in financial cost and in 
standards development, continues to be spent to overcome this barrier. 
 Analysis of computerized alerts over time illustrated the impact of increased 
resources on workflow process and nurse response time.  After 2007, not only was the 
rejection rate of alerts significantly decreased, but the response time to alerts for new or 
overdue laboratory testing decreased.  When an employee was dedicated to entering 
laboratory data into the EHR, alerts were received sooner and the response time 





sending a reminder of laboratory testing to patients by letter.  Transplant programs with 
computerized alerting systems may consider implementing a process for reviewing the 
data generated by alerts to hasten the identification of resource misallocations. 
 By the end of the study period, the proportion of overdue tacrolimus alerts 
increased while the proportion of new tacrolimus alerts decreased.  In addition, the 
distribution of specific tacrolimus alerts differed: alerts for low tacrolimus results 
remained stable, but alerts for normal and high tacrolimus results decreased.  Overall, the 
proportion of alerts for low (20.4%) or high (2.9%) tacrolimus laboratory results readily 
outnumbered the alerts for normal (6.9%) tacrolimus results.  This is particularly 
unexpected when there was a decline in the number of new patients and an increase in the 
proportion of patients who have likely had sufficient time posttransplant for providers to 
maintain patients within the target range.  Patient noncompliance is a possible but 
unlikely explanation.  These unexpected differences may also be explained by a 
mismatch between the unaltered logic of automated rules that trigger the alerts and 
revised clinical practice.  The protocol for immunosuppression had been revised since the 
automated rules had been implemented, with a downward shift in the target range.  Under 
the revised protocol, nurse transplant coordinators were receiving alerts for low 
tacrolimus results that were no longer considered below the target range.  The automated 
rules triggering computerized alerts should be updated when the laboratory monitoring 
protocol is revised.  This process may be semiautomated by periodically reviewing 
generated alerts to identify mismatches of clinical practice and the logic of automated 
rules. 





main determinant of the desired target range for immunosuppression.  In practice, 
however, nurse transplant coordinators adjust this target range based on certain 
conditions (eg, Hepatitis C positive status).  The target range for tacrolimus is manually 
decreased for postliver transplant patients with these conditions.  Coordinators must 
determine whether a patient is positive for these conditions before knowing whether the 
alert is valid or should be adjusted.  Alerts may be improved by further personalizing the 
logic based on these conditions. 
 Alert fatigue among physicians is a well-known unintended consequence of 
alerting systems.
17–19
  While methods for reducing alert fatigue have been 
demonstrated,
20,21
 the problem persists.  One recommendation to minimize alert fatigue is 
to provide alerts that are noninterruptive.
22
  The alerting system analyzed in this study 
used noninterruptive alerts, or "notifications," that nurse transplant coordinators viewed 
in an electronic inbox.  This may have contributed to the 100% response rate and the 98% 
acceptance rate for the alerts received by nurse transplant coordinators.  In addition, alerts 
were delivered in a team-based environment to support transplant patient management 
and were designed specifically to support this workflow.
10
  After ten years of experience 
with the alerting system, nurse transplant coordinators continue to use the system for 
patient management. 
 This observational study has limitations.  First, the study included only patients 
who were transplanted at one institution and who received monitoring of 
immunosuppressive care from the same institution.  This population may not be 
representative of patients at other transplant centers.  Second, our definition of patients 





included in the study. 
 
3.6 Conclusion 
 As patients progress after liver transplantation, overdue laboratory testing 
becomes more prevalent.  Alerts should be capable of supporting providers as they 
monitor the evolving needs of posttransplant patients over time.  Opportunities exist to 
further improve computerized alerts by maintaining the logic used by existing alerts and 
by including additional parameters as transplant clinical management practices advance.  
Implementation of automated laboratory reporting for a greater proportion of reported 












Table 3.1. Distribution of patients and immunosuppression management alerts, by year 

























2005 38 338 14220 42.1 39.0 19.6 18.1 7.0 
2006 38 357 14344 40.2 39.3 16.5 23.0 4.3 
2007 40 372 14733 39.5 40.4 16.9 28.3 4.5 
2008 40 387 15749 40.7 43.1 19.7 25.9 0.6 
2009 37 403 16518 41.0 45.3 21.3 24.6 0.5 
2010 29 402 16146 40.2 44.2 25.1 19.4 0.1 
2011 29 409 15740 38.5 43.1 25.6 21.6 0.2 
2012 26 418 16632 39.8 45.6 29.3 21.9 0.2 











Table 3.2. Description of immunosuppression management alerts generated  
from January 1, 2005-December 31, 2012 
 
Alert Message Alert Count 
(%) 





Overdue for tacrolimus testing 15010 (12.1%) 0.2% 99.8% 16.7% 8.5% 
Overdue for creatinine testing 12217 (9.8%) <0.1% >99.9% 50.0% 8.3% 
Creatinine (increased by 0.3 since 
last result) 
3912 (3.2%) 42.5% 57.5% 0% 0.5% 
Creatinine (increased by 0.3 
between three results) 
1409 (1.1%) 48.5% 51.5% 0% 0.1% 
Creatinine (no significant increase)  46139 (37.2%) 30.2% 69.8% <0.1% 0.4% 
Tacrolimus (below target range) 25932 (20.9%) 24.6% 75.4% <0.1% 0.2% 
Tacrolimus (within target range) 8034 (6.5%) 18.0% 72.0% 0% 0.2% 
Tacrolimus (above target range) 3791 (3.1%) 27.2% 72.8% 0% 0.9% 
New cyclosporin A 2806 (2.3%) 28.4% 71.6% 0% 0.3% 
New sirolimus 232 (0.2%) 13.8% 86.2% 0% 0% 
Potassium (below target range) 2261 (1.8%) 64.5% 35.5% 0% 1.1% 
Potassium (above target range) 521 (0.4%) 55.7% 44.3% 0% 2.2% 
Magnesium (below target range 
within 30 days posttransplant) 
1204 (1.0%) 21.3% 78.7% 0% 1.7% 










Table 3.3. Summary of reasons given for rejecting or accepting immunosuppression 
management alerts, by hospitalization status when the alert was generated 
Patient hospitalized when alert generated Patient not hospitalized when alert generated 
Rejected Accepted Rejected Accepted 
Overdue laboratory testing alerts: 
57%: No reason 
given 
43%: Non IHC 
labs available 





4%: Letter notification 
4%: Patient in hospital 




Labs available but 
not yet entered 
into EHR 
13%: No reason 
given 
13%: Lab testing 
interval extended 
by clinician 
57%: Patient previously 
notified, waiting for labs 
37%: Letter notification 
3%: Unsuccessful phone 
call 
2%: Phone notification 
1%: No reason given 
<1%: Left message on 
messaging system 
<1%: Left message with 
household contact 
<1%: Spoke with 
patient 
<1%: In person 
notification 
<1%: Patient in hospital 
New laboratory testing alerts: 
100%: No 
reason given 
100%: No action 
required 
48%: Reviewed labs 





<1%: Lab results 
already seen and acted 
upon 
76%: No reason 
given 
29%: Lab data 
charted 
incorrectly 
47%: No action required 
42%: Reviewed labs 
39%: Contacted patient 
14%: Consulted 
physician 
5%: No reason given 
5%: Lab results already 










Table 3.4. Distribution of immunosuppression management alerts generated while patients were not  
hospitalized, by year 
 






























OD | New 
2005 11650 31.9 23.9 18.7 | 8.9 | 5.3 2.6 | 0.7 | 35.3 4.6 29.4 | 2.0 
2006 11052 30.3 21.4 21.9 | 8.9 | 3.9 2.4 | 0.8 | 36.1 4.7 25.0 | 0.3 
2007 10569 29.0 23.5 22.1 | 8.2 | 3.4 2.8 | 1.0 | 35.0 4.1 26.5 | <0.1 
2008 11666 32.0 26.6 21.6 | 6.7 | 2.9 2.0 | 0.7 | 34.3 5.3 2.5 | 0.2 
2009 12450 34.1 28.2 19.3 | 7.6 | 3.1 1.9 | 0.7 | 34.6 4.5 2.2 | 0.1 
2010 13017 35.7 31.1 21.1 | 6.5 | 2.1 2.3 | 0.7 | 32.8 3.4 0.3 | 0.1 
2011 12345 33.8 32.6 21.3 | 5.2 | 1.6 2.3 | 0.7 | 32.1 4.1 0.6 | 0.1 
2012 12987 35.6 37.5 18.0 | 3.8 | 1.2 2.5 | 0.7 | 29.8 6.6 0.5 | 0.1 
Total 95736 32.8 28.4 20.4 | 6.9 | 2.9 2.4 | 0.8 | 33.7 4.7 8.4 | 0.4 
a. The combined proportion of alerts indicating overdue laboratory testing for tacrolimus or creatinine. 
b. The proportions of alerts that were (L) low, (N) normal, or (H) high compared to the target range for 
tacrolimus laboratory testing, respectively. 
c. The proportions of alerts that were for (*) an increase of 0.3 units between two creatinine results, 
(**) an increase of 0.3 units between three creatinine results, and (O) all other results for creatinine 
laboratory testing, respectively. 
d. The combined proportion of alerts indicating a new laboratory result for: magnesium, potassium, 
cyclosporin A, or sirolimus. 



























Patients with ≥1 








0-3 mo 272 25850 95 2.0 26.5 53.6 0.8 
3-6 mo 271 10130 37 13.4 41.7 30.4 4.0 
6-12 mo 273 10538 39 6.4 46.5 19.9 1.1 
1-2 yr 288 11950 41 13.1 63.9 11.4 3.4 
2-3 yr 280 10283 37 25.1 68.6 15.5 3.4 
3-4 yr 264 8752 33 35.6 75.0 11.9 3.3 
4-5 yr 249 6622 27 24.2 54.2 17.0 1.5 
5-6 yr 231 5092 22 25.0 46.8 12.7 1.2 
6-7 yr 221 4749 21 35.1 50.2 10.7 1.0 
7-8 yr 200 4375 22 33.5 55.5 14.5 1.5 
8-9 yr 193 3941 20 35.9 59.1 13.6 2.6 
9-10 yr 174 3700 21 35.3 60.3 11.4 2.9 
10+ yr 193 18100 94 44.1 82.4 13.5 1.6 


















Figure 3.1. Time between a new laboratory testing alert for non-hospitalized patients and 
















Figure 3.2. Time between an overdue laboratory testing alert for non-hospitalized 













Figure 3.3. Time between a new laboratory testing alert for non-hospitalized patients and 














Figure 3.4. Time between an overdue laboratory testing alert for non-hospitalized 













Figure 3.5. Time between the first in a series of overdue tacrolimus laboratory testing 









1.  U.S. Department of Health and Human Services. OPTN/SRTR 2012 Annual Data 
Report.; 2012. Available at: http://srtr.transplant.hrsa.gov/ADR.aspx. 
2.  Marshall B, Swearingen JP. Complexities in transplant revenue management. Prog 
Transplant. 2007;17(2):94–8. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/17624131. Accessed February 26, 2014. 
3.  Centers for Medicare and Medicaid Services. Meaningful Use. 2014. Available at: 
http://www.cms.gov/Regulations-and-
Guidance/Legislation/EHRIncentivePrograms/Meaningful_Use.html. 
4.  Blumenthal D, Tavenner M. The “Meaningful Use” Regulation for Electronic 
Health Records. N Engl J Med. 2010;363(6):501–4. doi:10.1056/NEJMp1006114. 
5.  Kawamoto K, Lobach DF. Proposal for fulfilling strategic objectives of the U.S. 
Roadmap for national action on clinical decision support through a service-
oriented architecture leveraging HL7 services. J Am Med Inform Assoc. 
2007;14(2):146–55. doi:10.1197/jamia.M2298. 
6.  Kawamoto K, Houlihan CA, Balas EA, Lobach DF. Improving clinical practice 
using clinical decision support systems: a systematic review of trials to identify 
features critical to success. BMJ. 2005;330(7494):765. 
doi:10.1136/bmj.38398.500764.8F. 
7.  Greenes RA, ed. Clinical Decision Support: The Road Ahead. 2nd ed. Amsterdam: 
Academic Press; 2014. 
8.  Teich JM, Osheroff JA, Pifer EA, Sittig DF, Jenders RA. Clinical decision support 
in electronic prescribing: recommendations and an action plan: report of the joint 
clinical decision support workgroup. J Am Med Inform Assoc. 2005;12(4):365–76. 
doi:10.1197/jamia.M1822. 
9.  Osheroff JA, Teich JM, Middleton B, Steen EB, Wright A, Detmer DE. A 
roadmap for national action on clinical decision support. J Am Med Inform Assoc. 
2007;14(2):141–5. doi:10.1197/jamia.M2334. 
10.  Staes CJ, Evans RS, Narus SP, Huff SM, Sorensen JB. System analysis and 
improvement in the process of transplant patient care. Kuhn KA, Warren JR, 
Leong T-Y, eds. Stud Health Technol Inform. 2007;129(Pt 2):915–919. Available 
at: http://www.ncbi.nlm.nih.gov/pubmed/17911849. Accessed March 4, 2014. 
11.  Staes CJ, Evans RS, Rocha BHSC, et al. Computerized alerts improve outpatient 
laboratory monitoring of transplant patients. J Am Med Inform Assoc. 
2008;15(3):324–32. doi:10.1197/jamia.M2608. 





 manual entry of structured, coded laboratory data from multiple sources into an 
ambulatory electronic health record. J Am Med Inform Assoc. 2006;13(1):12–5. 
doi:10.1197/jamia.M1813. 
13.  Staes CJ. Development of an information system for the outpatient management of 
liver transplant patients [dissertation]. Salt Lake City: University of Utah; 2006. 
Available at: http://gradworks.umi.com/32/03/3203433.html. Accessed July 26, 
2012. 
14.  Park ES, Peccoud MR, Wicks KA, et al. Use of an automated clinical management 
system improves outpatient immunosuppressive care following liver 
transplantation. J Am Med Inform Assoc. 2010;17(4):396–402. 
doi:10.1136/jamia.2009.000992. 
15.  Jacobs J, Weir C, Evans RS, Staes C. Assessment of Readiness for Clinical 
Decision Support to Aid Laboratory Monitoring of Immunosuppressive Care at 
U.S. Liver Transplant Centers. Appl Clin Inform. 2014;5(4):988–1004. 
doi:10.4338/ACI-2014-08-RA-0060. 
16.  Cresswell K, Majeed A, Bates DW, Sheikh A. Computerised decision support 
systems for healthcare professionals: An interpretative review. Inform Prim Care. 
2012;20:115–128. doi:10.14236/jhi.v20i2.32. 
17.  Kuperman GJ, Reichley RM, Bailey TC. Using Commercial Knowledge Bases for 
Clinical Decision Support: Opportunities, Hurdles, and Recommendations. J Am 
Med Informatics Assoc. 2006;13(4):369–371. doi:10.1197/jamia.M2055. 
18.  Ash JS, Sittig DF, Campbell EM, Guappone KP, Dykstra RH. Some unintended 
consequences of clinical decision support systems. AMIA Annu Symp Proc. 
2007:26–30. doi:18693791. 
19.  Embi PJ, Leonard AC. Evaluating alert fatigue over time to EHR-based clinical 
trial alerts: findings from a randomized controlled study. J Am Med Informatics 
Assoc. 2012;19(e1):e145–e148. doi:10.1136/amiajnl-2011-000743. 
20.  Simpao AF, Ahumada LM, Desai BR, et al. Optimization of drug-drug interaction 
alert rules in a pediatric hospital’s electronic health record system using a visual 
analytics dashboard. J Am Med Inform Assoc. 2014;22(2):361–9. 
doi:10.1136/amiajnl-2013-002538. 
21.  Lee EK, Wu T, Senior T, Jose J. Medical Alert Management: A Real-Time 
Adaptive Decision Support Tool to Reduce Alert Fatigue. AMIA Annu Symp Proc 
2014. 2014:845–854. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/25954391. 
22.  Phansalkar S, van der Sijs H, Tucker AD, et al. Drug-drug interactions that should 





Am Med Informatics Assoc. 2012;(June 2010):489–493. doi:10.1136/amiajnl-






IMPACT OF COMPUTERIZED LABORATORY MONITORING ON  




 Liver transplant recipients require lifelong immunosuppressive care to prevent 
organ rejection, drug toxicity, and death.  Transplant centers face challenges when 
implementing immunosuppressive care protocols, monitoring laboratory data, and 
performing other information management tasks for this high-risk population.  Currently, 
transplant centers use manual paper-based processes to receive or track 
immunosuppressive laboratory results.
1
  These manual processes are not scalable and can 
lead to inefficiencies and deficiencies in information management.
2,3
  While concerns 
about information management for clinical decision making are not unique to 
immunosuppression management,
4–8
  they are exacerbated in the context of transplant 
patient care.  First, as the number of liver transplant recipients increases each year and 
long-term survival rates improve,
9
 transplant centers manage a growing population of 
transplant recipients generating information that must be prioritized and managed.  
Second, immunosuppressive care protocols have narrow therapeutic indices and complex 





conditions, and other factors.
1,10
  Information management challenges may impact the 
quality of lifelong immunosuppressive care, and may not be addressed by the 
“meaningful use” of electronic health record (EHR) systems incentivized by the HITECH 
Act.
11
  EHRs often merely coexist with paper-based systems
1
, adding complexity to the 
healthcare workflow. 
 The biomedical literature includes descriptions of computerized transplant 
management systems,
3,12–16
 but only two publications describe the use of more advanced 
clinical decision support (CDS) for postliver transplant immunosuppressive care.
3,12
  One 
publication describes the use of integrated information displays to support physicians and 
coordinators performing comprehensive immunosuppressive care review.
12
  Patients 
managed with the system experienced significantly fewer rejection episodes and 
tacrolimus toxicity events compared to patients managed with the prior paper charting 
system.  The second publication describes earlier work at Intermountain Healthcare (IH) 
by several authors of this paper regarding computerized notifications to support nurse 
transplant coordinators as they monitored immunosuppressive care.
3
  Notifications were 
implemented using a CDS infrastructure to automate laboratory monitoring protocols and 
were delivered to an inbox integrated within the EHR.  The system led to significant 
process improvements, such as improved completeness, timeliness, and reduced 




As of 2016, the liver transplant team at IH has continued to use the computerized 
notification and data entry system developed in 2004 to manage their growing population 
of over 500 active liver transplant patients.
17





accept an average of 40-50 notifications each day.  While the system was previously 
shown to improve care process measures, the relationship to clinical outcomes is 
unknown.  In addition, we have a unique opportunity to evaluate functionality that is 
becoming more commonly available in vendor-based EHRs.  Therefore, our objectives 
were to evaluate the association between implementation of computerized notifications 
and (a) compliance with the protocol-based laboratory testing schedule, (b) occurrence 
and response to toxicity episodes, and (c) occurrence of mortality and graft failure. 
 
4.2 Methods 
4.2.1 Study design, setting, and intervention 
 We conducted a retrospective cohort study with historical control to assess 
outcomes among liver transplant patients from Intermountain Healthcare (IH).  The IH 
transplant center serves the Intermountain West (UT, ID, WY, MT, NV, and CO) and 
was located in LDS Hospital until October 2007 when it was transferred to Intermountain 
Medical Center.  From January 1, 2001 to March 27, 2008, the number of postliver 
transplant patients actively managed by three IH nurse transplant coordinators increased 
from 250 to 420 patients. 
 Between routine outpatient visits, patients had a schedule for laboratory testing 
(Table 4.1) to be performed at a laboratory owned by IH or an external entity.  All 
laboratory results were recorded on a paper flow chart.  Beginning on March 12, 2004,  
new external laboratory results were also manually entered in the EHR using a structured 
data entry form, integrating IH and external laboratory results in the EHR.
18
 





triggered in real time based on protocol logic (Table 4.1) and delivered to an electronic 
inbox in the EHR.
3
  Notifications concerned new, out-of-range, and overdue laboratory 
testing, critical laboratory results, and other events important for immunosuppression 
management.  Implementation began on March 28, 2004, and integration into the 
clinician workflow was completed by November 1, 2004.  The computerized logic was 
unchanged during the study period. 
 
4.2.2 Study population 
 Between January 1, 2001 and March 27, 2008, 261 patients received their first 
liver transplant at IH and had their tacrolimus levels and testing schedules continuously 
monitored by IH coordinators (Figure 4.1).  We excluded 31 patients transplanted during 
the nine-month transition period for implementation and initial use of the notification 
system.  We excluded patients who died during initial hospitalization for transplantation 
or within three days following hospital discharge (n=14) or who switched from 
tacrolimus to another immunosuppressant prior to hospital discharge following their 
transplantation (n=3). 
 The study population included preintervention control (n=110) and intervention 
(n=103) patients, transplanted before and after the transition period, respectively (Figure 
4.1).  We censored patients after death (n=11), graft failure/liver retransplantation (n=2), 
changing from tacrolimus to another immunosuppressant (n=2), transferring routine 
immunosuppressive care to another transplant program (n=8), or becoming lost to follow-
up (n=7) (Table 4.2).  Unless censored, patients in the control and intervention groups 





 For analyses requiring laboratory data, we used a subset of the study population: 
patients for whom all tacrolimus testing was performed at an IH facility.  Test results 
from external laboratories were not available electronically for the control group, and 
differences may exist in testing patterns between those using an IH or an external 
laboratory.  In December 2004, one author (CS) compared all laboratory results 
documented on the transplant care paper flow charts with laboratory results available in 
the IH EHR.
18
  From this analysis, we identified the subset of patients (n=54 (49%)) in 
the control group with no tacrolimus results from an external laboratory (Figure 4.1).  We 
identified the subset of eligible patients (n=67 (65%)) in the intervention group using 
information about the testing facility documented in the EHR for each laboratory result. 
 
4.2.3 Data collection 
In 2014, we extracted data from the IH data warehouse: patient demographics, 
tacrolimus results, hospital admission and discharge dates, protocol status (ie, active or 
inactive), and risk factors determined to be important by a liver transplant physician 
(author GH) such as prior kidney transplantation or hepatitis C infection. For intervention 
patients, we extracted computerized notifications. If a patient had two or more tacrolimus 
results in a day, we selected the highest value or removed duplicate results (n=26; 0.3%). 









4.2.4 Primary outcomes and definitions 
 Primary outcomes included incidence of toxicity episodes or a missed due date for 
laboratory testing, time to respond to a toxic or an overdue tacrolimus test, and mortality 
and graft failure.  A toxicity episode was defined as one or more consecutive tacrolimus 
laboratory results greater than 20 ng/ml.  Potential days of follow-up are the time period 
between hospital discharge following liver transplantation and the end of the follow-up 
period, disregarding censoring.  Graft failure was defined to occur on the date of re-
transplantation.  Model for End-stage Liver Disease (MELD) is used to assess the 





4.2.5 Data analysis 
Unless otherwise indicated, we analyzed categorical variables using a Chi-square 
or Fisher’s Exact test and continuous variables using a t-test.  We used descriptive 
statistics to compare the study populations and describe computerized notifications. We 
classified tacrolimus results as “in-range” versus “out-of-range” and “on-time” versus 
“overdue” by emulating the protocol logic (Table 4.1) using Stata.20  We validated our 
classification with notifications generated for the intervention group.  Nearly all (98%) 
laboratory results triggered a notification.  Using Cohen’s kappa, we found significant 
agreement when classifying laboratory results as out-of-range (agreement: >99.9%; 
kappa>0.99, 95% CI: 0.96-1.02) or overdue (agreement: 99.3%; kappa=0.85, 95% CI: 
0.82-0.88) between the emulated and the computerized logic.  





included in the models: sex, age at transplantation, MELD score, hepatitis C status, days 
hospitalized following liver transplantation, days hospitalized during first year after liver 
transplantation, and categories of time since transplantation from the protocol.   
 The laboratory-based analyses included the subset of study patients who used an 
IH laboratory for all tacrolimus testing (Figure 4.1).  To compare the incidence of toxicity 
episodes and of missing a due date for laboratory testing, we fitted mixed-effects, 
multivariable Poisson regression models, with laboratory results across time nested 
within patients.  We controlled for the above variables and used backward-elimination for 
variable selection.  To analyze the impact on maintaining tacrolimus levels within target 
ranges, we compared (a) the distribution of tacrolimus levels, and (b) the first tacrolimus 
levels obtained after a missed due date.  To analyze the time to respond to a toxicity 
episode, we compared the distribution of time between the first tacrolimus result 
indicating a toxicity episode and the next tacrolimus result.  Similarly, to analyze the time 
patients were overdue, we compared the average time between the laboratory testing due 
date and the next result.  In a subgroup analysis, we stratified by time since 
transplantation. 
 To compare the relative risk of mortality and graft failure between control and 
intervention groups, we fit a Cox proportional hazards regression model and controlled 
for the above variables.  We used backward-elimination for variable selection with 
p=0.20 as the cut-off.
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4.2.6 Ethical review  
 Institutional Review Boards from Intermountain Healthcare and the University of 
Utah approved this study.  A waiver of informed consent was obtained. 
 
4.3 Results 
4.3.1 Description of study population and laboratory testing 
Among 261 patients who received their first liver transplant between January 1, 
2001 and March 27, 2008, 213 (82%) patients were included in the study (Figure 4.1).  
We found no difference in demographic characteristics or censoring events between 
study groups (Table 4.2).  However, the severity of chronic liver disease prior to liver 
transplantation for both study populations (p<0.01) and the potential days of follow-up 
for the full study population (p=0.03) were significantly higher among the intervention 
group (Table 4.2).  On average, intervention patients were sicker and were transplanted 
earlier in the follow-up period, allowing more time to elapse between transplantation and 
the end of the follow-up period.  A subset of 121 (57%) patients was included in the 
laboratory-based analyses.  This subset of patients generated 6,706 tacrolimus results and 
used an IH laboratory for all tacrolimus testing.  The demographic and clinical 
characteristics of the patients included in this subset were not significantly different than 
the set of patients excluded from this analysis because they had one or more of their 








4.3.2 Description of the computerized notifications 
 During the 39-month intervention period, coordinators received 46,872 
computerized notifications for their entire liver transplant population.  Therefore, the 
three coordinators each received an average of 93 notifications per week.  One third of 
the notifications (n=17,045; 36%) concerned patients in the intervention group selected 
for this study (Table 4.3). 
 Among all notifications for the intervention group, 7,507 (44%) concerned  
tacrolimus laboratory testing.  Most (n=6,804; 91%) of these notifications were for new 
tacrolimus results, of which 61% were below the target range.  The remaining 9% of 
tacrolimus-related notifications concerned overdue laboratory testing.  Coordinators 
responded to all, and ‘accepted’ 95%, of the tacrolimus-related notifications.  There was a 
significant difference between the full intervention group and the subset of the 
intervention group concerning the proportion of notifications for overdue tacrolimus or 
creatinine laboratory testing.  Otherwise, similar patterns were observed for the subset 
included in the laboratory-based analyses (Table 4.3). 
 
4.3.3 Compliance with the laboratory testing schedules 
 During the first six months posttransplant, the incidence rate of missing a due date 
for laboratory testing per 1000 patients-days was lower for the intervention group, but 
this difference was not statistically significant (Table 4.4).  Conversely, after 180 days 
(ie, six months) posttransplant, the incidence rate of being overdue was higher in the 
intervention group (p<0.01) (Table 4.4).  However, in a mixed-effects, multivariable 





since transplantation, we found no significant risk of being overdue associated with 
computerized notifications (adjusted rate ratio=1.10; 95% CI: 0.90-1.34; p=0.37). 
The average number of days from a missed due date to the next laboratory result 
was not significantly different across groups for any category of time since transplant 
(Table 4.4).  However, after a missed due date, the average tacrolimus concentration of 
the next laboratory result was significantly lower for the intervention group than for the 
control group 30-90 days posttransplant (10.0 vs. 14.4 ng/mL; p=0.02) and more than 90 
days posttransplant (7.4 vs. 9.7 ng/mL; p<0.01), and for both periods the control group 
was within the target range while the intervention group was below the target range 
(Table 4.4). 
 
4.3.4 Impact on the occurrence and responsiveness to tacrolimus  
toxicity episodes 
The average concentration (ng/mL) for tacrolimus levels was significantly lower 
among patients in the intervention group for each category of time since transplant 
(p<0.01) (Table 4.5).  For both groups, the average tacrolimus concentrations were below 
the target range during the first 30 days posttransplant but within the target range after 
this period (Table 4.5).  In addition, the incidence rate of toxicity episodes was 
significantly lower for the intervention group among laboratory testing performed more 
than 90 days posttransplant (p=0.02) (Table 4.5).  In a mixed-effects, multivariable 
Poisson regression model accounting for demographic and clinical variables and time 
since transplantation, use of computerized notifications was associated with fewer 





represented a 32% risk reduction. 
 The average time from a toxicity episode to the next laboratory result was always 
lower for the intervention group, but only significantly lower among laboratory results 
received 0-30 days and 30-90 days posttransplant (Table 4.5). 
 
4.3.5 Impact on mortality and graft failure 
 Overall, 13 patients expired or experienced liver graft failure during follow-up 
(Table 4.2).  The cumulative risk of the composite endpoint mortality or graft failure is 
displayed as a Kaplan-Meier graph (Figure 4.2).  Use of computerized notifications was 
associated with a 75% reduction in risk of mortality and graft failure in a multivariable 
Cox regression model (adjusted hazard rate=0.25; 95% CI: 0.06-0.95; p=0.042). 
 
4.4 Discussion 
 This is the first study to describe clinical outcomes associated with 
implementation of a computerized notification system for postliver transplant laboratory 
monitoring.  After implementation of the system, we observed a significant decrease in 
the time to respond to toxicity episodes during the first 90 days posttransplant, a 32% 
decreased relative risk of the occurrence of toxicity episodes, and a 75% decreased 
relative risk of mortality and graft failure.  These improvements are especially striking 
considering that the 1-year and 3-year relative risk of mortality and graft failure observed 
nationwide during about the same time period (2002-2006) decreased by less than 5%.
22
  
The 75% relative risk reduction we observed was approximately 15 times greater than the 





period.  During the study period, the composition of the transplant team and the written 
and computerized posttransplantation protocols did not change.  While multiple 
unexplained factors may have improved postliver transplant mortality rates, the 
computerized notifications may have indirectly improved clinical outcomes by 
automating and facilitating earlier identification of patients at risk and supporting 
workflow even as the number of patients being managed increased by 68% (from 250 to 
420 patients). 
 The computerized notification system was associated with a 32% reduction in the 
relative risk of toxicity episodes, which may lower the risk of subsequent renal failure or 
other side effects of drug toxicity such as mortality.
23
  We also found, however, that 
tacrolimus levels across each category of time since transplantation were significantly 
lower for intervention patients, indicating that clinical practice may have changed during 
the study period by lowering the target range for intervention patients.  While revised 
clinical practice likely impacted average tacrolimus concentration levels, computerized 
notifications may have also helped with early identification of rising tacrolimus 
concentration levels.  Perhaps more important, however, is the significant reduction in 
time to respond to toxicity episodes during the first 90 days posttransplant.  Both the 
average time to respond to a toxicity episode, as well as the variation in response time, 
decreased for patients in the intervention group.  Typically, postliver transplant 
immunosuppression therapy begins at a high concentration level that is tapered over 
time;
23
 therefore, the greatest risk of excessively high concentration levels occurs during 
the initial months following liver transplantation.  This risk pattern was consistent with 





notifications may have decreased the time to respond to toxicity episodes, particularly 
during the initial weeks following liver transplantation when risk is highest, by 
automating and decreasing the time to notify transplant coordinators about new 
laboratory results with excessively high concentration levels. 
 The relationship between computerized notifications and overdue laboratory 
testing is unclear.  Stratified analysis showed a nonsignificant decrease in the incidence 
of being overdue during the first six months, but a significant increase after six months 
posttransplant.  The computerized notification system is unlikely to increase the 
incidence of missed due dates because overdue notifications were not generated until 
days or weeks after a missed due date (see Table 4.1).  Other factors (eg, increased 
nursing workload while managing more patients) may have contributed to the increased 
incidence of missed due dates.  Even so, after missing a due date, computerized 
notifications were associated with an improved response time to get tested.  
Computerized notifications likely enabled quicker identification and response to overdue 
laboratory testing. 
 This study has limitations.  First, this study is assessing the impact of an 
intervention implemented 10 years ago.  Nevertheless, the findings are relevant for 
understanding the impact of automated CDS and population management tools currently 
promoted in ‘Meaningful Use’ legislation.11,24  In addition, the laboratory testing patterns 
observed in the study are similar to patterns observed through 2012 in another study 
published separately.
17
  Second, the historical control design may create imbalances that 
impact results.  In our study, patients in the intervention group had more severe liver 





notification system.  Third, potential historical effects not controlled for in our study may 
confound our findings.  We did not control for changes in surgical or clinical practice, 
donor factors, comorbidities not included in the analysis, or cause of death or graft loss.  
Therefore, while an association between the use of computerized notifications and 
changes in outcomes exists, we cannot assert that the notifications caused these changes.  
Fourth, we did not analyze the costs associated with entering external laboratory results 
as structured data into the EHR, and this is likely to vary widely among transplant 
centers.  Fifth, we only analyzed patients who received tacrolimus immunosuppression 
therapy.  However, over 90% of postliver transplant patients at IH were on tacrolimus 
immunosuppression therapy during the study period.  Sixth, for the laboratory result 
based analysis, we were required to exclude patients who were tested outside IH during 
the control period because their results are not available in computable format. However, 
we believe the findings are generalizable because we found no significant differences in 
the demographic and clinical characteristics of the population among those included and 
excluded from the subset used for laboratory-based analyses.  Finally, this study occurred 
at a midsized transplant center, and results may not be generalizable to all transplant 
centers.  An experimental design may yield greater confidence in determining the 
relationship between computerized notifications and clinical outcomes, but implementing 
such a design is not practical. 
 Despite these limitations, the notification system and the study have strengths that 
should be considered.  First, the computerized notifications were delivered to nurses, 
whereas most evaluations in the literature focus on CDS tools for physicians.  Targeting 
nurses, rather than physicians, spawned from a thorough system analysis,
2,25,26





played a critical role in the impact, high usage, and acceptance of the notification system.  
Second, even though the number of active liver transplant patients during the study 
increased 68% from approximately 250 to 420, the same number of coordinators (three) 
spent the same amount of time monitoring laboratory results.  The computerized 
notification system provides greater scalability for the processes of laboratory monitoring 
than the manual, paper-based approach used during the control period.  Third, other 
healthcare domains use similar clinical processes to manage laboratory results and 
medications, such as diabetes care or anticoagulation therapy.  We hypothesize that a 
similar CDS tool could improve clinical processes for other chronic care domains. 
 Transplant-specific computerized notifications delivered to nurse transplant 
coordinators are associated with improved care processes and clinical outcomes and 
provide greater scalability for laboratory monitoring workflow processes.  The utility of 
computerized notifications may be further improved by incorporating additional factors 
(eg, comorbidities, history of rejection, other medications, etc.) important for optimizing 





Table 4.1. Automated rules for generating notifications based on laboratory testing of 
immunosuppression, kidney function, and critical values 
 
Rule Time since liver 
transplantation 
(days) 
Notify if… Add additional message if… 
New 
Tacrolimus 
>0 and ≤30 New result 
received 
Result is:  
 <15 (below target range),  
 ≥15 and ≤18 (within target 
range), or  
 >18 (above target range) 
>30 and ≤90 Result is:  
 <12 (below target range),  
 ≥12 and ≤15 (within target 
range), or  
 >15 (above target range) 
>90 Result is:  
 <12 (below target range),  
 ≥8 and ≤12 (within target 
range), or  
 >12 (above target range) 
New 
Cyclosporine 










n/a New result 
received 
Increase greater than 0.3 between 
two consecutive levels within the 
past two months 
Increase greater than 0.3 between 
three consecutive levels within 





>0 and <90 
a
 14 days since 
last result 
 
≥90 and <180 a 21 days since 
last result 
 
≥180 and <1460 b 45 days since 
last result 
 
≥1460 c 120 days 




n/a <3.5  
High 
Potassium 
n/a >5.9  
Low 
Magnesium 
>0 and ≤30 <1.6  





Table 4.1 Continued 
 
a
  Notification of overdue testing is generated if no laboratory result is received 7 days 
after the due date.  An overdue notification is repeated every 3 days after the initial 
notification until a new laboratory result is received. 
b
  Notification of overdue testing is generated if no laboratory result is received 15 days 
after the due date.  An overdue notification is repeated every 14 days after the initial 
notification until a new laboratory result is received 
c
  Notification of overdue testing is generated if no laboratory result is received 30 days 
after the due date.  An overdue notification is repeated every 14 days after the initial 
















Table 4.2. Description of the study population and the subset of patients selected for 
laboratory-based analyses for whom all tacrolimus testing was performed at an 
Intermountain facility 
 





















Subpopulation that used 
an Intermountain 






0.02 N/A N/A N/A 
Male: % 61.8% 66.0% 0.53 66.7% 67.2% 0.95 












Model for End-stage 
Liver Disease [MELD] 
score immediately prior 













Patients with at least one 
positive Hepatitis C test 
result: % 
30.0% 23.3% 0.27 27.8% 26.9% 0.91 
Patients that underwent 
kidney transplant before 












Days hospitalized for 
liver transplantation 










Days hospitalized during 
first year after hospital 












Potential days of follow-










Patients who were 
censored during the 
follow-up period due to: 
number (%) 
      













Table 4.2 Continued 
 









































Laboratory tests per 100 
days of follow-up: mean 
(SD) 






 We imputed missing values of MELD scores for 25% of patients in the control group, as 
reporting was not required prior to February 2002.  Imputation is reliable up to 50% 
missing.
27
   Imputation was done using the truncated regression imputation method, 




 Other reasons include: change to another immunosuppressant, transfer to another 
transplant program, or lost to follow-up status. 





Table 4.3. Description of the computerized notifications delivered between January 1, 
2005 and March 27, 2008 for patients in the intervention groups 
 




Number of patients  103  67  
Total number of notifications generated 17,045  10,297  
Number of notifications generated for: #  
(%) 
 #  
(%) 
 





Overdue for creatinine testing 609  
(3.6%) 
 208  
(2.0%) 
 





Increased by 0.3 since last result*  571  
(7%) 
 325  
(7%) 
Increased by 0.3 between three 
results* 
 277  
(4%) 
 170  
(4%) 
No significant increase*  7,040  
(89%) 
 4,404  
(90%) 
New tacrolimus results 6,804  
(40%) 
 4,329  
(42%) 
 












New cyclosporin A 70  
(0.4%) 
 48  
(0.6%) 
 
New sirolimus 10  
(<0.1%) 
 9  
(<0.1%) 
 
Potassium (below target range) 281  
(1.6%) 
 173  
(1.7%) 
 
Potassium (above target range) 58  
(0.3%) 
 24  
(0.2%) 
 




 355  
(3.4%) 
 
Magnesium (below target range) 96  
(0.6%) 
 63  
(0.6%) 
 
     












Table 4.3 Continued 
 




Number of notifications generated for: #  
(%) 
 #  
(%) 
 
Number of notifications generated while 
patient was hospitalized (after discharge 




 2,888  
(28%) 
 














Table 4.4. Description of metrics related to being overdue for tacrolimus testing, 
among the subset of patients that used an Intermountain laboratory for all tacrolimus 
testing 
 
 Control Intervention p value 
Number of patients  54 67 - 
    
Incidence rate of being overdue for 
laboratory testing (per 1000 patient-days) 
   
Days posttransplant: >0 to <90 days 8.2 5.9 0.22 
Days posttransplant: ≥90 to <180 days 7.9 7.4 0.79 
Days posttransplant: ≥180 days to <4 
years 
7.0 9.4 <0.01 
    
Average number of days between a missed 
due date and the next laboratory result – 
mean (SD) 
   

















    
Average tacrolimus concentration (ng/mL) 
of next laboratory result after a missed due 
date – mean (SD)* 
   
Days posttransplant: >30 to ≤90 days 






Days posttransplant: >90 days 






















Table 4.5. Description of the occurrence and responsiveness to tacrolimus toxicity 
episodes, among the subset of patients that used an Intermountain laboratory for all 
tacrolimus testing 
 
 Control Intervention p value 
Number of patients  54 67 - 
Number of tacrolimus results  2,816 3,890 - 
    
Average tacrolimus concentration (ng/mL) for 
all laboratory results – mean (SD) 
   
Days posttransplant: >0 to ≤30 days 






Days posttransplant: >30 to ≤90 days 






Days posttransplant: >90 days 






    
Incidence rate of toxicity episodes (per 1000 
patient-days) 
   
Days posttransplant: >0 to ≤30 days 37.9 24.2 0.11 
Days posttransplant: >30 to ≤90 days 18.5 13.9 0.15 
Days posttransplant: >90 days 1.7 1.0 0.02 
    
Average number of hours between a 
tacrolimus laboratory result >20 ng/mL and 
the next laboratory result – mean (SD) 
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THE EFFECT OF COMPUTERIZED NOTIFICATIONS ON WORKFLOW  
PROCESSES OF OUTPATIENT POSTTRANSPLANT LABORATORY 
MONITORING OF IMMUNOSUPPRESSIVE CARE 
 
5.1 Background 
 While EHR use at liver transplant centers is nearly universal, paper-based 
processes continue to be used by all transplant centers to receive or track 
immunosuppression laboratory results.
1
  These paper-based processes are not scalable 
and can lead to inefficiencies and deficiencies in information management.
2
  In addition, 
paper records are prone to transcription errors, can only be located in one place at a time, 
and are not being amenable to computerized clinical decision support (CDS).
2
  
Regardless, nurse transplant coordinators are expected to carefully monitor a large and 
growing volume of laboratory testing results for their patient population.
3
 
 In 2001, Staes conducted a system analysis to assess the information system needs 
of the transplant center at Intermountain Healthcare (IH).
4
  Information management 
issues were discovered, and researchers identified an opportunity to improve the 
laboratory monitoring processes for posttransplant immunosuppressive care.  A 







  In particular, this system provided computerized 
notifications to automate the identification of immunosuppression or physiological 
function laboratory tests that were new, out-of-range, or overdue.  Evaluation studies of 
computerized notifications for laboratory monitoring found an association with 
improvements in process measures as well as clinical outcomes of postliver transplant 
patients.
2,5
  Also, there is evidence that a computerized notification system continues to 
be used long-term and that even a large volume of notifications is accepted by nurse 
transplant coordinators.
3
  However, we found no studies describing the effect of 
computerized notifications on the workflow of transplant coordinators.  In particular, it is 
unknown if the information management issues previously identified at IH are similar to 
those faced by coordinators at different transplant centers without a transplant-specific 
CDS system.  Evaluating workflow processes may help to identify opportunities to better 




 Transplant centers at University of Utah Health Care (UUHC) and IH are located 
in the same region of the United States and have performed a similar number of liver 
transplantations since 2010.
7
  Nurse transplant coordinators at UUHC have used the Epic 
outpatient EHR to manage the ambulatory care of their patient population since 2012.  
Conversely, coordinators at IH used a proprietary EHR called HELP2 with an integrated 
computerized notification system designed specifically for the posttransplant laboratory 
monitoring workflow.
2
  We sought to understand how workflow process measures of 
laboratory monitoring differed across similar transplant centers with different information 





transplant center without transplant-specific CDS and population management tools. 
 
5.2 Objectives 
 Our objectives were to: a) understand the workflow and data flow in transplant 
programs with and without transplant-specific laboratory monitoring CDS, b) measure 
the impact of transplant-specific CDS on laboratory monitoring process measures, 
particularly for those processes performed by the nurse transplant coordinators and those 
performed by their assistants, c) compare the satisfaction of transplant coordinators 
regarding their laboratory monitoring workflow, and d) evaluate usage of information 
provided in transplant-specific computerized notifications. 
 
5.3 Methods 
5.3.1 Study design, study population, and setting 
 We conducted prospective observational studies at two transplant centers: 
Intermountain Healthcare (IH) in Murray, UT, and University of Utah Health Care 
(UUHC) in Salt Lake City, UT.  Both transplant centers serve the Intermountain West.  
From January 1, 2010 to December 31, 2014, the transplant centers at IH and UUHC 
performed 152 and 133 liver transplantations, respectively (Table 5.1).  The study 
population included postliver transplant coordinators and assistants at both transplant 
centers.  At IH, the immunosuppressive care for approximately 600 postliver transplant 
patients was monitored by three coordinators with the aid of one assistant; at UUHC, the 
immunosuppressive care for approximately 250 postliver transplant patients was 





between pre- and posttransplant patients) providing the equivalent of 2.5 full-time effort.  
The size of the patient populations varied because liver transplantation started earlier at 
IH (1986) than at UUHC (2006).  At both transplant centers, assistants supported the 
work of coordinators by entering new laboratory results into the EHR or paper record, 
requesting reports from laboratory facilities, calling patients to request laboratory testing, 
and managing the schedule of patient visits to the outpatient clinic.  The proportion of 
laboratory results received from an external laboratory facility was approximately twice 
as high at UUHC compared to IH (Table 5.1).  
 
5.3.2 Computerized notifications 
 Prior to November 1, 2004, coordinators at IH identified new laboratory results by 
receiving a faxed laboratory report or by searching for them in the EHR or paper record 
of a patient.  On November 1, 2004, IH researchers implemented a transplant-specific 
computerized notification system along with a data entry application to integrate external 
laboratory results into the EHR.  Since then, computerized notifications for new, out-of-
range, and overdue immunosuppression or physiological function laboratory tests have 
been delivered to an electronic inbox within the IH EHR (see example in Figure 5.1).  
Notifications were generated for patients who had been enrolled in an electronic registry.  
Coordinators were informed of all new laboratory results available in the EHR in one 
place without checking individual patient records.  Conversely, coordinators at UUHC 
relied on a general EHR notification system to identify new laboratory results available 
from the UUHC laboratory.  UUHC coordinators also identified new laboratory results 





in the EHR or paper record of a patient. 
 
5.3.3 Development of workflow process diagrams 
 To understand the workflow processes of laboratory monitoring, coordinators 
from each transplant center were observed over a 1-week period during the Fall of 2015.  
The observations included short interviews during which coordinators were asked to 
explain what they were doing and their purpose for performing the task.  A workflow 
process diagram was generated and iteratively refined by observation of and feedback 
from coordinators until no new processes related to laboratory monitoring were 
identified. 
 
5.3.4 Data collection 
 To record process measures associated with receiving laboratory reports and 
entering laboratory data into the EHR or other information systems, we created a data 
collection form (Appendix A) that was used by transplant assistants.  The form identified 
whether a laboratory report contained a laboratory result for immunosuppression or 
creatinine and whether each result had been previously seen.  To ensure understanding of 
the data collection form and method, we modeled the steps and observed the assistants as 
they recorded data on the form using recently received laboratory reports.  Finally, we 
asked each assistant to record a new entry on the data collection form each time a 
laboratory report was received from an external laboratory facility and entered into the 
EHR.  Since patients at UUHC were more likely to get laboratory testing at an external 





collected data for a month. 
 Based on the workflow processes identified, we created another data collection 
form (Appendix A) to record the events that triggered coordinators to check for new 
laboratory results and whether new immunosuppression laboratory results were 
identified.  We interviewed coordinators from each transplant center to determine days 
and times when tasks related to postliver transplant monitoring, evaluation, and reporting 
would be performed in the administrative office setting.  We selected five consecutive 
workdays for observation at each transplant center (UUHC: October 7-13, 2015; IH: 
October 14-20, 2015), and coordinators confirmed that the workdays were expected to be 
representative of a normal week.  We excluded observations when coordinators were 
attending hospital rounds, outpatient clinic visits, or other scheduled time during which 
laboratory monitoring was not the primary activity.  Observations were performed in 
blocks, the size of each block in hours was equal to the number of coordinators (UUHC: 
two; IH: three), and we randomly assigned each coordinator to a single one-hour interval 
within each block.  Before data collection, each coordinator was given a document 
indicating the data elements that would be collected during observations and was asked to 
communicate these data elements each time the coordinator was looking for new 
laboratory results.  During observations, we explicitly asked coordinators for these data 
elements if not provided.  After the five-day observation period, coordinators were asked 
to complete a questionnaire regarding their satisfaction with performing specific tasks 
associated with laboratory monitoring using their current information systems (Appendix 
B).  For coordinators at IH, the questionnaire had an additional section about the 





a picture of a typical notification message, and each data element referenced in the 
questionnaire was uniquely identified with a number (Appendix B). 
 
5.3.5 Outcomes 
 The outcomes concerning the workflow of transplant assistants were designed to 
measure inefficiencies related to receiving, reviewing, and entering external laboratory 
reports into the EHR or other information systems.  The outcomes were: 
1. the distribution of delivery methods of laboratory results,  
2. the proportion of times that no new immunosuppression or creatinine laboratory 
results were identified in newly received external laboratory reports that contained 
immunosuppression or creatinine results, and 
3. the time from specimen collection to data entry of external laboratory results into 
the EHR. 
 The outcomes concerning the workflow of transplant coordinators were designed 
to measure inefficiencies and satisfaction with monitoring laboratory results.  The 
outcomes were: 
1. the distribution of events triggering a search for new immunosuppression 
laboratory results,  
2. the proportion of unsuccessful searches for new immunosuppression laboratory 
results,  
3. the time from specimen collection to identification of new immunosuppression 
laboratory results,  





5. the frequency of usage of each data element provided in computerized 
notifications. 
 
5.3.6 Data analysis 
 We compared categorical variables using a Chi-square test (or Fisher’s exact 
test when appropriate) and compared continuous variables using a Wilcoxon rank-sum 
test.   Analyses were performed using Stata 14.1.
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  We defined the data entry response 
time as the time between specimen collection and the time the assistant manually entered 
the laboratory result into the EHR as recorded during observations.  We defined the 
coordinator response time as the time between specimen collection and the time the 
coordinator acted on the laboratory result as recorded during observations.  We compared 
coordinator response time using only new laboratory results from internal laboratory 
testing facilities to control for differences in the proportion of laboratory testing done at 
external laboratories and differences in laboratory processing and reporting time. 
 Using the questionnaire, we measured satisfaction of performing tasks using a 7-
point Likert scale and reported the proportion of responses that were a 6 or 7 (“Mostly 
satisfied” or “Very satisfied,” respectively) as well as the range of responses.  The labels 
for the other options were: “Slightly satisfied,” “Neither satisfied nor dissatisfied,” 
“Slightly dissatisfied,” “Mostly dissatisfied,” and “Very dissatisfied.”  We summarized 
suggestions for improving tasks for laboratory monitoring.  We also measured the 
frequency of usage of each data element in a notification message using a 5-point Likert 
scale with the labels “Rarely or never,” “Infrequently,” “Sometimes,” “Often,” or 





description.  We summarized these responses and identified data elements within the 
notification message that received the highest or lowest usage by all coordinators. 
 
5.3.7 Ethical review 




5.4.1 Description of laboratory monitoring workflow processes 
 The laboratory monitoring workflow process follows a similar pattern at both 
transplant centers (Figure 5.2).  We identified seven general steps: 
1. A patient has blood drawn. 
2. The laboratory facility receives the blood sample, processes the laboratory test, 
and creates a laboratory report based on the test results. 
3. The laboratory sends the report to the transplant center. 
4. The laboratory report is received by the transplant center. 
5. The laboratory report is integrated into the EHR and/or a paper flow sheet. 
a. Reports from an external laboratory are: 
i. Automatically integrated into the EHR (if an electronic interface 
has been established with the laboratory); otherwise, manually 
entered into the EHR. 
ii. Manually transcribed to a paper flow sheet, or an updated paper 





b. Reports from an internal laboratory are: 
i. Automatically integrated into the EHR. 
ii. Manually transcribed to a paper flow sheet or an updated paper 
flow sheet is printed from an electronic paper flow sheet. 
6. A transplant coordinator reviews the flow sheet and identifies a new or overdue 
laboratory testing result. 
7. A transplant coordinator takes appropriate action. 
For a more detailed process diagram and a step-by-step narrative specific to each 
transplant center, see Figure 5.3 (UUHC) or Figure 5.4 (IH).  We identified seven major 
differences in the laboratory monitoring workflow at the two transplant centers (Table 
5.3). 
 
5.4.2 Process measures about entry of external laboratory data  
by transplant assistants 
 Among newly received external laboratory reports that were being processed for 
data entry by a transplant assistant, the proportion of laboratory reports that resulted in 
identification of no new laboratory results was significantly lower at IH (Table 5.4).  At 
IH, duplicate immunosuppression drug levels were only reported for 4.3% of the results 
compared with 23% of the results at UUHC (p<0.01) (Table 5.4).  Conversely, for newly 
received external laboratory reports that were being processed for data entry by a 
transplant assistant, the response time from specimen collection to data entry in the EHR 
was significantly lower at UUHC than at IH (p<0.01) (Table 5.4).  At IH, the median 





at UUHC (p<0.01).  Similar patterns of duplicate reports and response times were found 
for laboratory reports with creatinine laboratory results (Table 5.4). 
 
5.4.3 Process measures about checking for new laboratory  
results by transplant coordinators 
 From October 7, 2015 to October 20, 2015, we collected 301 searches by 
coordinators for new laboratory results (UUHC: 138; IH: 163) (Table 5.5).  Of these, 168 
(56%) were searches for new immunosuppression laboratory results (UUHC: 57; IH: 
111).  Each coordinator at UUHC checked for new laboratory results an average of 14 
times per day while each coordinator at IH checked an average of 11 times per day. 
 For coordinators at UUHC, the most common triggers for checking for new 
laboratory results were receiving a computerized notification for any new laboratory 
result (59%), remembering to check laboratory testing for a specific patient (15%), and 
being reminded by seeing a paper chart that was previously set aside (9%) (Table 5.5).  
Conversely, for coordinators at IH, the most common triggers were receiving a 
computerized notification for an immunosuppression or a physiological function 
laboratory test (48%), receiving a paper chart delivered by a transplant assistant (33%), 
and being reminded by seeing a paper chart that was previously set aside (9%) (Table 
5.5).  Of note, when an assistant at IH delivered a paper chart to a coordinator, the 
assistant was usually notified by checking for computerized notifications for new 
laboratory results which were then transcribed to the paper flow sheet.  The notifications 
were delivered to an electronic inbox that was accessible to the coordinators and the 





for new laboratory results 81% of the time. 
 
5.4.4 Impact of computerized notifications on unsuccessful  
searches for new immunosuppression laboratory results 
 Overall, there was no significant difference between UUHC and IH in the 
proportion of unsuccessful searches by coordinators for new immunosuppression 
laboratory results (n (%): UUHC: 56 (16%); IH: 111 (14%); p=0.66) (Table 5.5).  When 
stratified by trigger, there were also no significant differences in the proportions of 
unsuccessful searches (Table 5.5). 
 
5.4.5 Impact of computerized notifications on response time to  
new immunosuppression laboratory results received 
 We found differences in response times of coordinators to new 
immunosuppression laboratory results performed at an internal laboratory facility.  Most 
(n=121, 72%) of the immunosuppression results we evaluated were for tacrolimus blood 
concentration levels.  Coordinators at IH had a significantly shorter response time to new 
tacrolimus results than was observed at UUHC (median (IQR) [n]: UUHC: 23 (22-25) 
hours [11]; IH: 9 (6-26) hours [63]; p=0.049) (Table 5.5). There was no significant 
difference in the response time to new cyclosporine results between the two sites. 
 Everolimus is an immunosuppressant that had not yet been included into the logic 
for the notification system at IH.  We found that coordinators at UUHC had a 
significantly shorter response time to new everolimus results (median (IQR) [n]: UUHC: 





5.4.6 Satisfaction with laboratory monitoring using current  
information systems 
 Transplant coordinators at IH expressed greater satisfaction with the support they 
received performing posttransplant laboratory monitoring tasks with their current 
information systems (Table 5.6).  Among eight key tasks performed using the current 
information systems, the two coordinators at UUHC were less than “Mostly satisfied” or 
“Very satisfied” with each of the tasks with the exception of one coordinator who 
reported being “Mostly satisfied” with identifying patterns of laboratory results over time 
(Table 5.6).  In contrast, one or more of the three coordinators at IH were “Mostly 
satisfied” or “Very satisfied” with six of the eight key tasks (Table 5.6).  When asked 
how they would improve the task of identifying patients with new laboratory testing 
results, coordinators at both sites indicated that there was a lag between when a new 
laboratory result is available and when a notification is received by the coordinator that 
could be minimized or eliminated.  In addition, a coordinator at IH expressed a desire to 
receive notifications for other laboratory tests, a functionality that was already part of the 
information system at UUHC.  Finally, when asked how they would improve the task of 
identifying patients who were overdue for laboratory testing, UUHC coordinators 
expressed an interest in receiving a notification as well as sending notifications that 
informed patients (eg, via a patient portal) regarding upcoming or missed laboratory 
testing due dates.  Coordinators at IH asked for the ability to adjust the computerized 







5.4.7 Usage of data elements in IH computerized notification  
messages 
 The coordinators at IH were queried about their usage of data elements included 
in the transplant-specific computerized notifications (see Appendix B).  The laboratory 
test date/time, name, and value, and the hospitalization status were used most frequently 
(Table 5.7).  The least frequently used data elements included the patient contact 
information, the value of the laboratory results relative to the target range 
(above/within/below), the target range, and the alert status.  When we inquired about low 
usage of data elements concerning target ranges, the coordinators reported that the target 
ranges had changed over time and that the protocol they use no longer matched the target 
ranges encoded in the logic of the computerized notifications. 
 We found that among the information provided in the computerized notifications, 
each data element was used at least “Sometimes” by one or more of the three 
coordinators (Table 5.7).  We expect that different coordinators used data elements 
provided in notifications to satisfy different workflows or information needs. 
 
5.5 Discussion 
 Our study describes the laboratory data flow processes of two midsized transplant 
centers and compares the processes of posttransplant immunosuppressive care and their 
association with a transplant-specific computerized notification system.  We also 
assessed satisfaction using performance of specific tasks identified in the workflow 
analysis as the metric.  This allowed us to better ensure task-technology fit and to identify 
areas of improvement with greater validity.
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performed similar numbers of liver transplantation procedures in recent years, these 
procedures have been actively performed for twenty years longer at the IH transplant 
center and therefore the coordinators at IH collectively managed twice as many patients 
as the coordinators at UUHC.  Transplant-specific computerized notifications were 
associated with a different response time by coordinators to new tacrolimus laboratory 
results – the main immunosuppressant used – and a higher satisfaction of performing 
tasks related to posttransplant laboratory monitoring. 
 Transplant team members at UUHC were significantly more likely to review 
duplicate laboratory results from an external laboratory facility.  At IH, laboratory reports 
were reviewed first by an assistant and duplicates were discarded, so duplicate reports 
were never reviewed by transplant coordinators.  Conversely, UUHC coordinators were 
given each external laboratory report to review for urgency before reports were given to 
an assistant.  This may hasten response times to laboratory results indicating an urgent 
need, but it also means that the coordinators must review every result, including those 
that would be identified as a duplicate report by the assistant and discarded.  Regarding 
the time from specimen collection to data entry for external laboratory results, both new 
immunosuppression results and creatinine results were ready to be viewed in the EHR 
sooner at UUHC.  These times are likely impacted by multiple factors, such as the 
responsiveness of external laboratory facilities and how well the data entry capacity of 
the transplant center meets the demand of laboratory testing.  Integration of external 
laboratory results into the EHR may be significantly improved by implementation of an 
electronic interface with external laboratory facilities, however this may be neither 







 Of the triggers that coordinators used to search for new immunosuppression 
laboratory results, there was no significant difference between the transplant centers 
regarding the proportion of unsuccessful searches for new immunosuppression laboratory 
results.  This finding may be related to the fact that when a patient has blood drawn for 
posttransplant laboratory monitoring, both immunosuppression and physiological 
function tests are usually included in the same order.  However, immunosuppression 
laboratory results are often received a few hours or more after creatinine and other 
physiological function laboratory results arrive.  Thus, the arrival of creatinine laboratory 
results informs transplant coordinators that new immunosuppression results are expected 
within a few hours.  In addition, transplant coordinators usually know the times of day 
that immunosuppression laboratory results are processed and sent by a laboratory facility 
to the transplant center.  Therefore, predicting the arrival of new immunosuppression 
laboratory results may be easier and less likely to benefit from a transplant-specific 
computerized notification system.  In contrast, a transplant-specific computerized 
notification system may have a lower proportion of unsuccessful searches when 
physiological function test results are received, although this was not measured.  
Regardless, coordinators should be accessing information that adds value to their 
workflow.  If the available information has already been seen, then effort is wasted by 
coordinators searching for new information. 
 While coordinators at IH responded more quickly to new tacrolimus laboratory 
results, coordinators at UUHC were quicker to respond to new everolimus laboratory 
results.  There are two factors to consider regarding these differences.  First, while 





becoming more popular as a primary or a secondary immunosuppressant at transplant 
centers.  Second, IH coordinators rely on the list of computerized notifications to identify 
new immunosuppression laboratory results; thus, other laboratory results not received as 
a computerized notification may be missed or have a lower priority and searching for 
these laboratory results may be less frequent.  This was validated during observations: 
each time a patient had a pending everolimus laboratory result, coordinators at IH placed 
the patient’s chart in a marked bin, and multiple days passed before coordinators 
reviewed some of these charts and looked for everolimus results in the EHR.  The 
response time to new everolimus laboratory results would likely be improved by 
generating computerized notifications for this laboratory test similar to the notifications 
generated for tacrolimus.  It is important to note that we did not analyze differences in lab 
turn-around times at internal laboratory facilities, and we assumed that differences were 
related to workflow after new laboratory results were received by the transplant center. 
 Differences in laboratory data flow processes may have impacted process 
measures of the study.  At both transplant centers, new results from an internal laboratory 
facility were automatically integrated into the EHR and the transplant-specific 
information system.  The UUHC coordinators often had to manually check a list of 
laboratory results to identify new results.  On the other hand, IH coordinators received 
computerized notifications for all patients to inform them of newly available laboratory 
results.  We discovered a potential drawback of the workflow at IH: if a coordinator acted 
on a notification for a new laboratory result but did not have access to the paper flow 
sheet, there was a risk that the transplant assistant would view the computerized 





patient chart to the transplant coordinator.  This resulted in the coordinator reviewing the 
patient chart even though the newly transcribed laboratory result had already been seen 
by the coordinator.  Another significant finding was the difference in the distribution of 
triggers used to determine when to check for new or overdue laboratory results.  While 
computerized notifications could be generated regarding any laboratory result for any 
patient for UUHC coordinators, in practice, this was uncommon.  In addition, these 
coordinators relied on several different triggers to identify new laboratory results.  
Conversely, coordinators at IH relied on two triggers to identify most laboratory results, 
and these triggers relied directly or indirectly on computerized notifications.  While the 
proportion of unsuccessful searches for new immunosuppression laboratory results was 
not significantly different, relying on several different triggers may decrease response 
time.  In addition, some triggers require more effort to update, such as an Excel 
spreadsheet or a whiteboard, and are prone to transcription errors. 
 Coordinators who relied on transplant-specific notifications of new, out-of-range, 
or overdue laboratory testing were associated with greater satisfaction with the support of 
their information systems, and this may be logical based on the differences of the two 
information systems and workflow processes we identified in this study.  However, we 
identified opportunities to improve the laboratory monitoring process at both transplant 
centers.  First, notifications systems should be flexible enough to support the evolving 
needs of clinical practice, such as changing laboratory testing schedules, shifting target 
ranges, or inclusion of new immunosuppressants or laboratory tests without requiring 
significant involvement of information technology (IT) staff.  Second, developers and 





available in the EHR and when a notification is generated.  Third, notifications should be 
sent to patients regarding upcoming laboratory testing due dates, not just after the 
laboratory testing due date has been missed. 
 Our analysis also identified the usage of specific data elements provided in 
transplant-specific computerized notifications at IH.  We found that coordinators 
exhibited different patterns with using specific data elements.  Therefore, when gathering 
requirements to design a new system, we recommend that feedback be sought from all 
transplant team members, not just one coordinator or the manager of a transplant center.  
This strategy will ensure that data elements included in transplant-specific computerized 
notifications will meet the distinct information management needs of coordinators.  
Furthermore, we suggest that implementers periodically analyze the usage of data 
elements provided in notification messages.  This assessment may facilitate the 
identification of mismatches between the information needs of transplant coordinators 
and the information provided in notification messages.  In particular, we suggest that for 
data elements that are infrequently used, implementers seek feedback from coordinators 
regarding how the information may be improved, whether data elements may be added to 
or removed from the notification messages, and whether the logic of the notification 
system remains accurate. 
 This study has limitations.  First and foremost, we did not assess the completeness 
of reporting about new laboratory results that should have been reported to the transplant 
coordinators.  Our assessment focused on workflow concerning results that were reported 
or identified, but we do not know the impact of the transplant-specific notification system 





would require further analysis of tests that were performed.  Additional limitations were 
identified.  For example, second, we analyzed the workflow processes and information 
systems at two midsized transplant centers, and these may not be similar to those used by 
other transplant centers.  Third, we performed our observational study of the coordinators 
at each transplant center for only one week.  Additional observations may have greater 
statistical power to identify differences in process measures and outcomes, especially for 
less common processes or laboratory tests.  Fourth, we analyzed the usage of data 
elements by transplant coordinators provided in computerized notifications at one 
transplant center with three coordinators, and the patterns of usage may not be 
generalizable.  However, this notification system has been in use for over ten years, has a 
high response rate by coordinators,
3
 and other transplant centers are beginning to 
implement population management tools that provide similar data elements.  Thus, this 
analysis can be used to inform the information management needs of coordinators at 
other transplant centers. 
 
5.6 Conclusion 
 We have outlined critical differences in the laboratory monitoring workflow at 
transplant centers with and without access to transplant-specific computerized 
notifications.  These computerized notifications are associated with a faster response time 
of identifying new tacrolimus laboratory results by transplant coordinators.  Coordinators 
with access to a transplant-specific notification system were each managing nearly twice 
as many patients, yet we identified a high level of satisfaction with use of a transplant-





identified opportunities to improve how computerized notification systems may facilitate 












Table 5.1. Description of transplant centers, as of November 2015 




Year of first liver transplantation 2006 1986 
Number of liver transplantations performed 
between January 1, 2010 and December 31, 
2014 
133 152 
Number of actively managed postliver 
transplant patients 
~250 ~600 
Number of nurse transplant coordinators (full 
time equivalents) 
2 3 
Number of transplant assistants (full time 
equivalents) 
2.5 1 
Proportion of laboratory results received 
















Figure 5.1. Example of a notification message triggered by a new laboratory result for 





Table 5.2. Data elements included in computerized notifications provided to nurse 
transplant coordinators at Intermountain Healthcare 
Data Element Description 
Demographics 
 
Sex, age, and date of birth 
Contact information Home and work phone numbers 
Link to the patient record Opens the patient record in the EHR 
Date/time of laboratory 
test 
Date and time of the specimen collection for the laboratory 
test 
Severity Indicator to help prioritize notifications.  Levels of severity 
are assigned to notification messages using one of the 
phrases: 




Laboratory test The name of the laboratory test performed 
Laboratory value The value of the laboratory result 
Laboratory value relative 
to target range 
Value of the laboratory result compared to the target range 
for the time since transplantation using one of the phrases: 
 “below target range” 
 “within target range” 




The range of tacrolimus concentration levels defined in the 
clinical protocols used by the transplant team.  The ranges 
change based on time since transplantation. 
Transplant date Date of most recent liver transplantation 
Time since 
transplantation 
Number of days, months, or years since the most recent 
date of liver transplantation  
Hospitalization status Indicator of whether the patient is currently hospitalized at 
an internal facility 
Alert status An indicator of whether the notification was new or revised 
Triggering information Provides a link to the EHR data that triggered the 
notification (eg, the laboratory data) 
Accept or Reject button Allows the coordinator to indicate that they accept the 
notification and document the actions taken or reject the 
notification and document the reason 
Comment button Allows the coordinator to comment on the information 






























1. Actor: Patient Action: Draw blood sample 





Action: Receive blood sample, process laboratory test, 
and create laboratory report 
 The blood sample is received by an external (non-UUHC) laboratory facility, the 
laboratory test is processed, and a laboratory report is created and stored in the 





Action: Fax/mail laboratory report 
 The laboratory report is sent to the ordering clinician at the UUHC Transplant 
Center via fax, mail, or other method. 
4. Actor: PDA/MA Action: Call non-UUHC laboratory facility to request 
laboratory report 
 If an expected laboratory report was not received by the transplant center, the 
patient diagnostic assistant (PDA) or medical assistant (MA) calls the external 




Action: Give laboratory report to TC 
 Newly received laboratory reports are given to or collected by the transplant 
coordinator (TC). 
6. Actor: TC Action: Review laboratory report for urgency 
 The TC reviews the laboratory report for any laboratory results that indicate an 
urgent healthcare situation and takes action, if necessary. 
7. Actor: TC Action: Give laboratory report to MA 
 The TC gives the laboratory report to the MA for data entry. 
 





8. Actor: MA Action: Determine if laboratory report was previously 
seen 
 The MA determines if the laboratory report is a duplicate laboratory report that 
has already been received. 
9. Actor: MA Action: Shred duplicate laboratory report 
 If the laboratory report is a duplicate, it is shredded. 
10. Actor: MA Action: Enter new report into Epic and file report in 
paper chart 
 If the laboratory report is a not a duplicate, the MA manually enters the laboratory 
results into the Epic EHR, scans the laboratory report and attaches the scanned file 
to the patient chart, then files the laboratory report in the paper chart. 
11. Actor: MA Action: Print new paper flow sheet 
 The MA prints a new paper flow sheet and places it in a bin to be collected by the 
TC. 
12. Actor: UUHC 
laboratory 
facility 
Action: Receive blood sample, process laboratory test, 
and create laboratory report 
 The blood sample is received by an internal (UUHC) laboratory facility, the 
laboratory test is processed, and a laboratory report is created and stored in the 





Action: Integrate laboratory results into Epic EHR 
 The laboratory results are automatically entered into the Epic EHR. 
14. Actor: Epic EHR Action: Integrate laboratory results into eChart 
 The laboratory results are automatically entered into the patient record in eChart. 
15. Actor: Epic EHR Action: Make laboratory results available in electronic 
flow sheet 
 The laboratory results are available to the TC in the electronic flow sheet. 
 





16. Actor: Epic EHR Action: Generate computerized notification 
 If the TC ordered the laboratory tests in the EHR, a notification is generated and 
available to the TC in a list; otherwise, this notification is only available if it is 
forwarded by the ordering clinician to the TC. 
17. Actor: TC Action: Collect new paper flow sheet 
 The TC collects the new paper flow sheet from the bin. 
18. Actor: TC Action: Review computerized notifications 
 The TC reviews the list of computerized notifications for new laboratory results. 
19. Actor: TC Action: Trigger to look for new laboratory results 
 The TC is triggered by other events to look for new laboratory results. 
20. Actor: TC Action: Review Epic/eChart/paper flow sheet for new 
lab results 
 A trigger causes the TC to review the Epic EHR/eChart/paper flow sheet to look 
for new laboratory results. 
21. Actor: TC Action: Determine if new laboratory result is available 
 The TC determines if a new laboratory result is available. 
22. Actor: TC Action: Take action to resolve any health concerns 
 If a new laboratory result is available, the TC takes action to resolve any health 
concerns (eg, reviews laboratory results and other patient information to identify 
health concerns, communicates assessment of laboratory data to physician, 
informs patient, documents actions taken and plan of care changes in EHR and 
paper chart). 
 















1. Actor: Patient Action Draw blood sample 
 A posttransplant patient gets their blood drawn. 
2. Actor: Non-IH 
laboratory 
facility 
Action: Receive blood sample, process laboratory test, 
and create laboratory report 
 The blood sample is received by an external (non-IH) laboratory facility, the 
laboratory test is processed, and a laboratory report is created and stored in the 
laboratory information system of the external laboratory facility. 
3. Actor: Non-IH 
laboratory 
facility 
Action: Fax/mail laboratory report 
 The laboratory report is sent to the ordering clinician at the IH transplant center 
via fax, mail, or other method. 
4. Actor: TA Action: Call non-IH laboratory facility to request 
laboratory reports 
 If an expected laboratory report was not received by the transplant center, the 
transplant assistant (TA) calls the external laboratory facility to request that the 
laboratory report be sent to the transplant center. 
5. Actor: TA Action:  Collect laboratory report 
 Newly received laboratory reports are given to or collected by the transplant 
coordinator (TC). 
6. Actor: TA Action: Determine if laboratory report was previously 
seen 
 The TA determines if the laboratory report is a duplicate laboratory report that 
has already been received. 
7. Actor: TA Action: Shred duplicate laboratory report 
 If the laboratory report is a duplicate, it is shredded. 
 







8. Actor: TA Action: Enter new results onto paper flow sheet and 
into CDR, and file laboratory report into the 
patient chart 
 The TA transcribes the laboratory results onto the paper flow sheet, files the 
laboratory report in the paper chart, then manually enters the laboratory results 
into the CDR 
9. Actor: IH 
laboratory 
facility 
Action: Receive blood sample, process laboratory test, 
and create laboratory report 
 The blood sample is received by an internal (IH) laboratory facility, the 
laboratory test is processed, and a laboratory report is created and stored in the 
laboratory information system of the internal laboratory facility. 
10. Actor: Laboratory 
information 
system 
Action: Integrate laboratory results into EHR 
 The laboratory results are automatically entered into the EHR. 
11. Actor: EHR Action: Make laboratory results available in electronic 
flow sheet 
 The laboratory results are available to the TC in the electronic flow sheet. 
12. Actor: EHR Action: Generate computerized notification 
 If a new laboratory report includes a result for certain immunosuppression or 
physiological function laboratory tests, a notification is generated and is available 
to the TC in a single list. 
13. Actor: TA Action: Transcribe laboratory results onto paper flow 
sheet 
 The TA reviews the list of notifications and transcribes the laboratory result to 
the paper flow sheet. 
14. Actor: TA Action: Deliver new paper flow sheet to TC 
 The paper flow sheet is delivered to the TC at set times each day. 
15. Actor: TC Action: Review computerized notifications 
 The TC reviews the list of computerized notifications for new laboratory results. 
 





16. Actor: TC Action: Trigger to look for new laboratory results 
 The TC is triggered by other events to look for new laboratory results. 
17. Actor: TC Action: Review electronic/paper flow sheet for new lab 
results 
 A trigger causes the TC to review the EHR/ paper flow sheet to look for new 
laboratory results. 
18. Actor: TC Action: Determine if new laboratory result is available 
 The TC determines if a new laboratory result is available. 
19. Actor: TC Action: Take action to resolve any health concerns 
 If a new laboratory result is available, the TC takes action to resolve any health 
concerns (eg, reviews laboratory results and other patient information to identify 
health concerns, communicates assessment of laboratory data to physician, 
informs patient, documents actions taken and plan of care changes in EHR and 
paper chart). 
 





Table 5.3. Differences in laboratory monitoring workflow between transplant centers 
Occurrence in  
Workflow Process 
University of Utah Health 
Care 
Intermountain Healthcare 
1. Actions before data 
entry of external 
laboratory results 
Coordinator checks results to 
assess urgency of needed 
actions 
 
2. Data entry of 
external laboratory 
results – additional 
steps after assistant 
manually enters 
external laboratory 
results into EHR 
Assistant manually enters 




Assistant prints a new paper 
flow sheet and sets it in bin 
for coordinator 
Assistant transcribes results to 
paper flow sheet and sets it in 
bin for coordinator 




Coordinator prints new paper 
flow sheet printed 
Coordinator or assistant 
transcribes new laboratory 
results to paper flow sheet 




All laboratory results All tacrolimus and sirolimus 
immunosuppression and 
creatinine results and selected 
physiological function results 
5. Patients for whom 
computerized 
notifications were 
generated and sent 
directly to the 
coordinator 
Patients for whom the 
coordinator ordered the 
laboratory test in the EHR 
Any patient enrolled in the 
transplant management 
protocol (ie, the patient record 
number was added to the 
patient list) 
6. Triggers for 
determining when 
to check for new or 
overdue laboratory 
results 
Coordinator remembered to 
pick up new paper flow sheets 
printed by the assistant 
Assistant delivered the patient 
chart to the coordinator 
Coordinator checked a 
manually updated Excel 
spreadsheet to track 
laboratory testing due dates 
for each patient 
 
Coordinator maintained a 
whiteboard to track laboratory 
testing frequencies of certain 
patients 
 
7. Person who can 
view computerized 
notifications 
The clinician who ordered the 
laboratory test 











Table 5.4. Workflow and process measures associated with entry of external laboratory 
results by transplant assistants 
 UUHC* IH p value 
Number of assistants performing data entry 1 1  
Number of weeks observed  2 4  
Total number of laboratory reports reviewed 170 91  
 Number of laboratory reports reviewed 
with an immunosuppression result 
92 46  
 Number of laboratory reports reviewed 
with a creatinine result 
111 76  
Method of delivery of immunosuppression 
laboratory results – n (%)    
 Fax 92 (100%) 41 (89%) <0.01 
 Mail - 5 (11%) <0.01 
Method of delivery of creatinine laboratory 
results – n (%) 
   
 Fax 111 
(100%) 
70 (92%) <0.01 
 Mail - 6 (8%) <0.01 
Proportion of newly received external laboratory 
reports with immunosuppression and creatinine 
results that, in fact, contained no new 
immunosuppression or creatinine laboratory 
results: - n (%) 
   
 Immunosuppression 22 (24%) 2 (4%) <0.01 
 Creatinine 37 (33%) 9 (12%) <0.01 
Time from specimen collection to data entry of 
new laboratory results (hours) - median (IQR)    










* At UUHC, 176 laboratory reports were reviewed. However, due to missing data, we 





Table 5.5. Description of posttransplant laboratory data monitoring measures of nurse 
transplant coordinators 
 UUHC IH p value 
Number of nurse transplant coordinators 2 3  
Number of hours observed (per transplant center) 35 34.5  
Number of times searching for new laboratory 
results 
136 163  
Proportion of checks for new immunosuppression 






Distribution of triggers for checking for new 
immunosuppression laboratory results - % (n)   
 
 Received notification for any new 




<0.01  Received notification for a new 
immunosuppression or physiological 









 Reminded by a paper flow sheet that was 






 Remembered to check laboratory testing 











Proportion of unsuccessful searches for new 






 Received notification for any new 




0.27  Received notification for a new 
immunosuppression or physiological 











 Reminded by a paper flow sheet that was 






 Remembered to check laboratory testing 

















Table 5.5 Continued 
 
 UUHC IH p value 
Internal Laboratory Results only 
Response time to a new immunosuppression 
laboratory result (hours) - median (IQR) [n] 
   































Table 5.6. Satisfaction with using the current information systems for postliver  
transplant laboratory monitoring 
 
 University of 





How satisfied are you with the support of your 
current information systems to perform the 
following tasks: 
% Mostly or Very satisfied 
(Range*) 


































Identifying the target range of an 





Generating a list of all patients who are 





*Based on a 7-point Likert scale: 1 – very dissatisfied; 2 – mostly dissatisfied; 3 – 
slightly dissatisfied; 4 – neither satisfied nor dissatisfied; 5 – slightly satisfied; 6 – mostly 











Table 5.7. Frequency of usage of data elements in notifications provided to nurse 










How often do you use the 
information in the notification 
message when it is presented to 
you*: 
   
[1] Demographics 33% 0% 67% 
[2] Contact information 67% 33% 0% 
[3] Link to the patient record 0% 33% 67% 
[4] Date/time of laboratory test 0% 0% 100% 
[5] Severity 0% 33% 67% 
[6] Laboratory test 0% 0% 100% 
[7] Lab value 0% 0% 100% 
[8] Lab value relative to target 
range (above/within/below) 
33% 67% 0% 
[9] Target range 33% 67% 0% 
[10] Transplant date 0% 67% 33% 
[11] Time since transplantation 33% 33% 33% 
[12] Hospitalization status 0% 0% 100% 
[13] Alert status** 50% 0% 50% 
[14] Triggering information 0% 33% 67% 
[15] Accept or Rejection button 0% 0% 100% 
[16] Comment button 0% 100% 0% 
*Based on a 5-point Likert scale: 1 – rarely or never; 2 – infrequently; 3 – sometimes; 4 – 
often; 5 – always or almost always. 
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 With an increasing population of liver transplant recipients and improving long-
term survival rates, transplant centers must manage a growing pool of transplant 
recipients with an increasing volume of information.  Traditional methods of information 
management rely on manual, paper-based processes which are ill-suited to meet the 
complex needs of posttransplant immunosuppressive care.  Electronic health records 
(EHR) and clinical decision support (CDS) systems may better meet the information 
management needs of posttransplant laboratory monitoring while a system-agnostic CDS 
approach may be leveraged to disseminate these systems to transplant centers nationwide.  
Our motivation was to inform the development and implementation of transplant-specific 
CDS systems.  However, we identified several prerequisite questions regarding 
transplant-specific CDS for which we found no answers in the literature.  We conducted 
research studies with the goal of answering these questions. 
 The findings of these studies have indicated the feasibility of using a system-
agnostic CDS approach as well as provided suggestions for the development or 
enhancement of information systems for posttransplant care.  While a system-agnostic 
approach may be used to develop a transplant-specific CDS tool, EHR vendors are 





EHR systems that may provide some of the features desired.  However, it is likely that 
these systems are still lacking features we have identified as desirable within the 
posttransplant workflow, and thus our recommendations presented below may be useful 
for enhancing the functionality of these current systems. 
 
6.1 Significance 
 The objectives of the research described in this dissertation were met, and our 
findings inform the development of CDS systems intended to support the information 
management needs of the posttransplant laboratory monitoring workflow.  The 
nationwide survey revealed the ubiquity of both paper-based processes and electronic 
health records (EHR) for managing posttransplant immunosuppressive care.  The survey 
also showed that transplant programs used guidelines for laboratory monitoring with 
similar patterns of logic that can be implemented using rule-based computerized CDS.  
The longitudinal analysis was successful in showing how the distribution of alerts 
evolved over time and that CDS systems tailored to a workflow may be useful to target 
users for several years even without significant improvements or technical modifications.  
The cohort study demonstrated that a computerized notification system for laboratory 
monitoring was associated with improvements in the mortality and toxicity rates of 
posttransplant patients.  While changes in clinical practice may have impacted this 
change, we observed these improvements despite a large volume of patients and an 
intervention group with more severe chronic liver disease overall.  In addition, this study 
showed that computerized notifications may provide greater scalability to posttransplant 





transplant-specific computerized notification system was associated with improved 
response time, and differences in the functionality of the systems that may explain this 
finding.  The questionnaire showed that a transplant-specific notification system 
promoted greater satisfaction with performing tasks associated with laboratory 
monitoring, and that the usage of data elements in computerized notifications should be 
assessed to determine whether information needs of transplant coordinators are met.  
These studies produced recommendations to inform the development of transplant-
specific CDS systems. 
 
6.2 Recommendations 
 Given the prevalence of EHR use in transplant centers, the functions of 
transplant-specific information systems should be integrated into EHRs and not provided 
in a separate information system.  These transplant-specific functions are generalizable 
beyond the posttransplant patient population, thus integration allows these functions to 
benefit other patient populations.  In addition, posttransplant patients also have general 
clinical needs, so the workflow of transplant coordinators may be improved by 
integrating transplant-specific functions with general clinical functions of an EHR instead 
of forcing the coordinator workflow to switch between an EHR and a transplant-specific 
information system.  Therefore, integration of the functions of transplant-specific 
information systems may improve patient safety, quality, and cost of care for 
posttransplant laboratory monitoring. 
 We recommend that the following requirements be considered when designing 





 Laboratory results data exchange: Ensure that laboratory results are recorded 
efficiently and accurately as discrete data and are available to EHRs; where 
feasible, automate laboratory data exchange by implementing electronic interfaces 
with laboratory facilities. 
 Population management: Allow clinicians to define a patient population and 
computerized notifications to be sent to clinicians when triggered by new data 
about that patient population. 
 CDS for laboratory results monitoring: Implement computerized notifications for 
new, out-of-range, and overdue laboratory testing to support laboratory results 
monitoring based on protocols used by the transplant team. 
 Flexibility of CDS logic: Design the logic of computerized notification systems to 
be flexible enough to allow transplant clinicians to revise the target ranges, adjust 
the expected laboratory testing frequency, or include additional laboratory tests 
for monitoring without requiring the involvement of information technology (IT) 
staff.  In addition, these systems should support advanced logic for triggering 
notifications based concurrently on multiple parameters (eg, time since 
transplantation and presence of specified comorbidities). 
 Performance of CDS: Transplant team members typically should not receive 
computerized notifications after the triggering laboratory result has already been 
reviewed in the EHR.  Minimize the time between when a new laboratory result is 
received in the EHR and when a computerized notification is generated. 
 Unread notification status: Transplant team members should be able to quickly 





yet acted upon and removed from the electronic notification inbox.  Provide a 
visual cue that differentiates computerized notifications as read or unread (as is 
common with the use of a bold font for unread email messages). 
 Governance of CDS logic: Ensure timely governance of CDS systems by linking 
changes of clinical practice (eg, decrease in target range of immunosuppression) 
to revision of computerized logic. 
 Monitoring of CDS systems: Couple CDS systems with a periodic process for 
monitoring the data generated by the system.  This monitoring may help to 
identify resource misallocations, mismatches in clinical practice and 
computerized logic, and other opportunities to improve processes of laboratory 
monitoring. 
Following these recommendations may improve the process measures and clinical 
outcomes of posttransplant laboratory monitoring by transplant coordinators. 
 
6.3 Future Work 
 While the research in this dissertation has answered our original research 
questions, it has also prompted new research questions warranting future work. 
 First, SMART on FHIR is a promising software platform for providing system-
agnostic CDS tools.
1
  For example, Cerner has committed to support the SMART 
platform and has unveiled an online sandbox to support development of SMART apps.  
Furthermore, several SMART apps have been released by developers from various 
healthcare provider organizations or software vendors.  However, research is needed to 





it is necessary to understand how broadly this platform is supported by vendor-based 
EHR systems and thus implementable in transplant centers nationwide. 
 Second, we hypothesize that providing prospective notifications regarding 
upcoming laboratory testing due dates directly to patients may improve patient 
compliance with testing.  However, patient use of EHR portals and the impact of 
prospective monitoring (rather than the current reactive monitoring when patients are 
overdue) are unknown.  Delivery of notifications may be accomplished through 
increasingly prevalent patient portals.  We propose a study regarding the impact on 
process measures and clinical outcomes of prospective notifications delivered to patients. 
 
6.4 Conclusion 
 In summary, we have systematically investigated major questions relevant to 
developing a transplant information system, and we have evaluated transplant 
information systems currently in operation in order to inform the development of new or 
enhanced transplant information systems for posttransplant immunosuppressive care.  
Our recommendations may improve the processes measures and clinical outcomes 
associated with posttransplant laboratory monitoring.  Furthermore, we have found that 
the information systems at transplant centers nationwide meet certain prerequisites 
necessary to use a system-agnostic CDS approach for disseminating features we 







1.  Mandel JC, Kreda DA, Mandl KD, Kohane IS, Ramoni RB. SMART on FHIR: a 
standards-based, interoperable apps platform for electronic health records. J Am 














DATA COLLECTION INSTRUMENTS TO ASSESS WORKFLOW  

































QUESTIONNAIRE TO ASSESS SATISFACTION OF USING CURRENT 


























Identifying patients with a new 
laboratory result 
☐ ☐ ☐ ☐ ☐ ☐ ☐ 
Identifying patients with an out-
of-range laboratory result 
☐ ☐ ☐ ☐ ☐ ☐ ☐ 
Identifying patients who are 
overdue for laboratory testing 
☐ ☐ ☐ ☐ ☐ ☐ ☐ 
Identifying the target range of an 
immunosuppressant for a patient 
☐ ☐ ☐ ☐ ☐ ☐ ☐ 
Identifying a patient’s time since 
transplantation 
☐ ☐ ☐ ☐ ☐ ☐ ☐ 
Identifying patients who are 
hospitalized 
☐ ☐ ☐ ☐ ☐ ☐ ☐ 
Identifying patterns of laboratory 
results over time 











2a. Can you use your EHR (e.g. Epic or HELP2) to generate a list of all patients who are currently overdue for laboratory testing? 
Yes (go to 2c)  No (go to 2b) 
 
 
2b. Do you have a different system to generate a list of all patients who are currently overdue for laboratory testing?  






















you with this 
system 
(mentioned in 
2a or 2b)? 
☐ ☐ ☐ ☐ ☐ ☐ ☐ 
 



















The table below shows information that is presented to you in a computerized alert for new or overdue immunosuppression laboratory 
testing.  How often do you use the information in the alert message when it is presented to you (e.g. if the information appears 









 Rarely or never Infrequently Sometimes Often Almost always or always 
[1] Demographics ☐ ☐ ☐ ☐ ☐ 
[2] Contact information ☐ ☐ ☐ ☐ ☐ 
[3] Link to the patient record ☐ ☐ ☐ ☐ ☐ 
[4] Date/time of laboratory test ☐ ☐ ☐ ☐ ☐ 
[5] Severity ☐ ☐ ☐ ☐ ☐ 
[6] Laboratory test ☐ ☐ ☐ ☐ ☐ 
[7] Lab value ☐ ☐ ☐ ☐ ☐ 
[8] Lab value relative to target 
range (above/within/below) 
☐ ☐ ☐ ☐ ☐ 
[9] Target range ☐ ☐ ☐ ☐ ☐ 
[10] Transplant date ☐ ☐ ☐ ☐ ☐ 
[11] Time since transplantation ☐ ☐ ☐ ☐ ☐ 
[12] Hospitalization status ☐ ☐ ☐ ☐ ☐ 
[13] Alert status ☐ ☐ ☐ ☐ ☐ 
[14] Triggering information ☐ ☐ ☐ ☐ ☐ 
[15] Accept or Rejection button ☐ ☐ ☐ ☐ ☐ 
[16] Comment button ☐ ☐ ☐ ☐ ☐ 
 
 
6. [Intermountain only] What suggestions do you have to improve the information represented within the computerized alerts for 
immunosuppressive care laboratory monitoring? 
